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Abstract
Carotid bodies contain blood oxygen-sensing cells expressing leptin and leptin receptor
isoforms. Whether leptin is involved in chemoreception in the carotid body is unknown.
Experiments were completed to investigate leptin signaling in carotid body glomus cells
during intermittent hypoxia (IH). Rats were subjected to IH for 8 hours/day for 1, 7, 95 days
or to systemic leptin injections. Immunohistochemical and Western bot analysis were used to
localize leptin, its receptors and downstream signaling proteins in glomus cells. IH resulted
in increased circulating and local leptin, increased activation of STAT3 and Fra-1 expression
suggesting an activation of a leptin signaling system within these cells. Captopril treatment
prior to IH eliminated the increased plasma and carotid body leptin in IH suggesting
angiotensin II may exert an effect on leptin in glomus cells. The data suggest that leptin
acting in the carotid body activates glomus cells and may play a modulatory role in the
chemoreflex.
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Chapter 1

1

Literature Review
1.1 Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is a common type of sleep-disorder characterized by
brief but repeated obstruction of the upper airway (Dempsey et al., 2010, 2012;
Mannarino et al., 2012). These upper airway obstructions may be a partial blockage
(hypopnea) or may result in a fully compromised airway occlusion (apnea), causing loud
snoring, sleep fragmentation and excessive daytime sleepiness (Mannarino et al., 2012).
Obstructions may occur due to both anatomic and neuromuscular influences. The human
pharynx is not supported by the skeletal system which is prone to collapse during
negative pressure (i.e. inhalation) and soft tissue build up, such as adipose tissue
(Mannarino et al., 2012). A previous study has found that a reduction in BMI in patients
with OSA resulted in a decrease in upper airway collapsibility events by over half
(Schwartz et al., 1991). Not surprisingly, a narrow airway is generally more predisposed
to obstruction than a larger one (Schwab et al., 1995). Additionally, abnormal activity of
tonic and phasic dilator muscles can result in recurring airway obstructions (van Lunteren
and Strohl, 1986).
OSA occurrence varies with differing populations and within age groups. OSA is
more prevalent in men than in women with an estimated 4% of men and 2% of women
aged 50 or over suffering from symptomatic OSA (Strollo & Rogers; 1996). However,
this population-based evaluation may be grossly underestimated as a patient must
undergo a formal sleep study in order for the diagnosis to be made. Additionally, many
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sufferers are asymptomatic and may not seek medical attention. The male pattern of body
fat distribution may account for the increased prevalence in men, particularly deposition
in the trunk and neck area. In the middle-aged population, the numbers may be as high as
20-30% of the population suffering from OSA while not presenting symptoms (Young et
al., 1997). To be diagnosed with OSA syndrome, one must experience 5 or more
apnea/hypopnea events per hour of sleep in the presence of accompanying symptoms
including excessive daytime sleepiness, fatigue or impaired cognition, or experience 15
apnea/hypopnea events per hour of sleep irrespective of additional symptoms (Park et al.,
2011).
Although OSA is not uncommon in children, it is usually due to adenotonsillar
hypertrophy (Marcus & Loughlin, 1996). Perhaps the single most important factor
affecting OSA risk is body weight. Weight gain of 10% increases the risk of developing
OSA by six-fold (Peppard et al., 2000a) and a 10% loss of body weight is estimated to
decrease the apnea/hypopnea index (events/hour) by 26% (Peppard et al., 2000a). Within
the obese population (BMI ≥ 30) (Wolk et al., 2003), approximately 40% experience
significant OSA and approximately 70% of OSA patients are obese (Vgontzas et al.,
1994), daunting numbers considering the obesity epidemic occurring in North America
and estimates suggesting 41% of Americans will be obese by 2015 (Nejat et al., 2009).

1.1.1 Cardiovascular Consequences of OSA
The chronic effects of OSA are more severe than the fragmented sleep and
daytime sleepiness. There are severe cardiovascular complications associated with the
condition. OSA has been correlated with major cardiovascular disorders including
hypertension (Moller et al., 2003; Peppard et al., 2000b), stroke (Redline et al., 2010),

3

atherosclerosis (Friedlander et al., 1999) and heart failure (Shahar et al., 2001) among
others. Indeed when compared with non-OSA counterparts, OSA patients present with
increased blood pressure during both night and daytime hours (Moller at al., 2003;
Peppard et al., 2000b).

1.1.2 Hormonal Changes Associated with OSA
During normal daytime breathing, sympathetic nerve activity (SNA) is elevated in
OSA patients (Somers et al., 1995; Leuenberger et al., 1995) which may be a contributing
factor for many of these cardiovascular complications. Increased SNA may contribute to
renin-angiotensin system activation, increasing circulating angiotensin II levels which
have been positively correlated with daytime blood pressure (Moller et al., 2003). OSA
syndrome also brings with it additional hormonal changes which may cause or exacerbate
the cardiovascular morbidities previously described. For example, compared to BMImatched controls, OSA patients experience increases in plasma leptin concentrations
(Phillips et al., 2000; Harsch et al., 2003), as well as increased circulating catecholamines
(Eisenberg et al., 1990; Carlson et al., 1993).

1.1.3 Treatment of OSA
Despite the severity of the complications associated with sleep apnea, there are
treatments which reduce or abolish these deleterious effects. Unfortunately treatment of
OSA is often overlooked due to lack of awareness of the condition, method of diagnosis
and method of treatment. The primary treatment of OSA is continuous positive airway
pressure (CPAP). CPAP consists of the patient wearing a mask during sleep, which exerts
positive pressure on the upper airway, maintaining the integrity of the upper airway
during sleep and thus encouraging proper airflow. OSA patients using the CPAP method
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have marked reductions in SNA and blood pressure (Somers et al., 1995; Moller et al.,
2003). CPAP treatment also reduces signs of atherosclerosis in patients suffering from
OSA (Drager et al., 2007), which may also serve to further reduce risk of stroke and
myocardial infarction. Furthermore, use of the CPAP mask reduces circulating leptin
levels even with no change in patient BMI (Cuhadaroglu et al., 2009; Harsch et al., 2003)
and catecholamines (Drager et al., 2007). Although the benefits certainly outweigh the
costs, CPAP prescription and compliance is limited by the unwillingness of patients to
attend sleep clinics for proper diagnosis, and the discomfort associated with sleeping
while wearing the apparatus.

1.1.4 Intermittent Hypoxia
When a person experiences closure of the airway, as found in OSA, he/she
experiences a decrease in blood oxygen tension as a result of the respiratory cessation.
This decreased oxygen state is known as hypoxia and within OSA the patient experiences
intermittent hypoxia (IH), repeated episodes of reduced arterial oxygen (Strollo and
Rogers, 1996). Although a patient will experience fragmented sleep as a result of micro
arousals restoring airway tone, IH is a major physiological insult associated with OSA
and thus further study is needed to fully understand the effects of OSA and the
mechanisms through which the comorbidities and mortalities develop. Recently, human
subjects were used in the study of IH. When exposed to 4 weeks of nocturnal IH, human
subjects presented with increased muscle SNA and increased vascular resistance
(Gilmartin et al., 2010) consistent with some of the symptoms of OSA. Most studies of
IH involve a rodent model, developed by Fletcher et al. (1992a). In this model, animals
are exposed to cycling levels of oxygen during their night cycles, mimicking the IH

5

during sleep experienced by OSA patients. The mechanism of signaling IH to blood
pressure responses was investigated by carotid sinus nerve (CSN) denervation and it was
found the blood pressure responses to IH in this model were abolished in animals
receiving the denervation but not in sham controls (Fletcher et al., 1992b). From this
study, it becomes clear the peripheral carotid chemoreceptor reflex is vital to the
hypertensive changes caused by IH in the animal model.

1.2 The Carotid Body Chemoreceptor Reflex
1.2.1 Central and Peripheral Chemosensitive Regions
Mechanisms of oxygen-sensing are critical to an organism’s survival, especially
when levels deviate from homeostatic norms. In cases of decreased oxygen, it is
imperative cardiorespiratory parameters be altered to ensure proper oxygen (O2)
saturation reaches vital organs including increasing mean arterial pressure (MAP) and
respiration rate. Multiple types of chemoreceptors exist to monitor blood O2 and carbon
dioxide (CO2) levels via pH to keep these values within homeostatic ranges.

1.2.1.1

Ventrolateral Medulla

Central chemoreceptors, localized to the ventrolateral surfaces of the medulla
(Schlaefke, 1981), are believed to play an integral role in CO2 monitoring through pH
changes of brain interstitial fluid (Feldman et al., 2003; Fencl et al., 1966). In fact, a very
small increase in CO2 above normal values results in rapid stimulation of respiratory
drive (Feldman et al., 2003).
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1.2.1.2

The Aortic Body

The aortic bodies are thought to be very similar to carotid body chemoreceptors
however very little is known about how these organs function (Piskuric & Nurse, 2012).
Additionally, previous studies have indicated a lack of functional aortic body
chemoreceptors in the rat (Sapru and Krieger, 1977). Studies on carotid bodies frequently
indicate a greater involvement in O2 sensing and are considered the primary sensors of
blood oxygen partial pressure (PO2) (Feldman et al., 2003; Piskuric and Nurse, 2012).
Due to previous IH studies using CSN denervation by Fletcher et al. (1992b) and the
apparent lack of function of aortic chemoreceptors in the rat (Sapru and Krieger, 1977)
this study will focus on carotid body chemoreceptors.

1.2.2 The Carotid Body
The concept of the carotid body was confirmed by Heymans & Bouckaert in
1930, who performed a variety of experiments on anesthetized dogs based on previous
findings that electrical stimulation of the carotid bifurcation region caused a reflex
stimulation of respiratory centres (Hering, 1927). The investigators found that occlusion
of the common carotid arteries produced reflex increases in blood pressure and
respiration however, occlusion of the common vertebral arteries did not affect blood
pressure or respiration (Heymans & Bouckaert; 1930). Upon carotid sinus denervation,
the reflex changes were abolished. These early studies suggested changes in blood
pressure and respiration are due to reflexes originating from the carotid sinus.

1.2.2.1

Anatomy

The carotid bodies are small, ovoid organs about 0.6 mm long x 0.4 mm wide in
the rat (Sapru and Krieger, 1977). These organs are located bilaterally at the bifurcation
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of the carotid artery into the internal and external branches, an area of high blood-flow
perfect for sampling of arterial blood. Not surprisingly, the carotid body is highly
vascularized and has been suggested to be the highest perfused organ per unit body
weight in an organism (McDonald, 1981). The carotid body receives blood supply from a
small branch of the external carotid artery and signals the CSN (McDonald, 1981), which
projects from the carotid body to the petrosal ganglion (PG) and joins the
glossopharyngeal nerve before it enters the cranium.
The carotid body is composed of lobules or clusters consisting of two cell types:
chemoreceptor type-I glomus cells (or chief cells) closely supported by type-II glial-like
cells. Type-I glomus cells are small (8-15µm) cells arranged in clusters containing
cytoplasmic vesicles (McDonald, 1981). These cells have morphological features,
including gap junctions (Abudara et al., 1999) that support a great deal of intercellular
communication. The lobule-like organization would suggest autocrine and paracrine
signaling likely influences their responses. Additionally, coupling, both electrical and
dye, between cultured cells and tissue slices has been demonstrated (Jiang and
Eyzaguirre, 2003). Since almost all type-I cells are dopaminergic, the majority of type-I
cells express tyrosine hydroxylase (TH), the enzyme involved in conversion of L-arginine
to L-dihydroxyphenylalanine which is a precursor for dopamine. Due to the high
expression of TH in type-I cells, this enzyme is frequently used in immunohistochemical
studies to identify type-I cells (Bolme et al., 1977).
Type-II cells are present in carotid bodies in much lower numbers than type-I
cells however they are distributed in tight proximity to the glomus cell clusters. It has
been suggested for every type-II cell in the carotid body there are 4 type-I cells
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(McDonald, 1981). Type-II cells, which lack vesicles, are elongated in shape and are
typically found surrounding clusters of type-I cells. Type-II cells were thought to
‘support’ type-I cells however the suggestion of type-II cells acting as stem cell
precursors for type-I cells has arisen (Pardal et al., 2007) as well as playing a potential
role in paracrine signaling (Xu et al., 2003). Although not directly oxygen-sensing, data
indicate that these type-II cells may play a much larger role than originally thought.

1.2.2.2

Afferent Projections of Carotid Body Chemoreceptors

The carotid body is heavily penetrated by nerve afferents of the CSN, a branch of
the glossopharyngeal nerve, cranial nerve IX. Many of these nerves end in direct
apposition to clusters of type-I cells. The somas of the CSN are located in the PG. During
chemoexcitation, carotid body afferent impulses travel along the CSN to the nucleus of
the solitary tract (NTS), a dorsal brainstem site of autonomic integration, a pathway
known as the peripheral or carotid chemoreceptor reflex (Ciriello et al., 1981). Here,
carotid body afferent signals are integrated with neural circuitry involved in blood
pressure and respiration regulation. As one would expect, the carotid body signal due to
low PO2 traverses the CSN, arrives in the NTS and affects autonomic outflow resulting in
increased respiration and blood pressure to ensure normal PO2 levels are restored and
enough O2 is delivered to vital areas of the organism (Gonzalez et al., 1994; Fitzgerald et
al., 2009).

1.2.2.3

Efferent Innervation of Carotid Body Chemoreceptors

The carotid body is a front-line responder to chemical stimuli and thus requires
afferent innervation for conveying these stimuli to the central nervous system (CNS). The
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carotid body also possesses efferent innervation, a lesser studied area of carotid body
signaling but important nonetheless.
The carotid body receives parasympathetic innervation from a plexus of neuronal
nitric-oxide synthase-positive nerve fibers located along the CSN and glossopharyngeal
nerve (Wang et al., 1993, 1995). These nerve fibers are distinct from the afferent CSN
innervating the afferent aspect of the carotid body. Data indicates these parasympathetic
nerves act by releasing nitric oxide (NO) onto type-I cells. NO influence on carotid body
cells is well characterized and results in inhibition and thus reduced CSN activity (Wang
et al., 1995; Kline et al., 1998; Prabhakar, 1999). Although the exact conditions in which
this efferent pathway is activated are not known, it has been discovered that adenosine
triphosphate (ATP) may activate these neurons by acting through P2X receptors
(Campanucci et al., 2006).
The role of sympathetic innervation of the carotid body is controversial, with
studies supporting either an inhibitory action (O’Regan, 1981) or a potentiation of carotid
body activity (Mitchell and McCloskey 1974; O’Regan, 1981). Indeed evidence seems to
point to an inhibitory role as sympathectomy has been shown to potentiate carotid body
activity (Hatcher et al., 1978) although others have shown no effect of sympathetic
denervation on chemoreceptor activity to brief hypoxic tests (Davies et al., 1982;
McQueen et al., 1989). In a previous experiment it was found that sympathetic activity to
the carotid body from the superior cervical ganglion occurred only during sustained
hypoxia of over 5 minutes (Cherniak et al., 1992), indicating an inhibition of the
chemoreflex by efferent sympathetic activity may only occur during prolonged hypoxia,
potentially acting as a brake on an overactive system.
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1.2.2.4

Type-I Cells of the Carotid Body

Type-I cells exhibit a complex and dynamic phenotype including expression of a
variety of cell surface receptors and potential signaling molecules involved in
chemotransduction. No transmitter has been identified as the peptide responsible for all
carotid body signaling; rather each plays its own role in modulating carotid body
signaling and thus transduction of chemoreceptor information to the CNS via the PG and
CSN (Figure 1.1).

Figure 1.1. Schematic diagram of the afferent carotid body chemoreceptor reflex. PO2 partial pressure of oxygen in the blood; CB: Carotid body; NTS: Nucleus of the solitary
tract.
Potential signaling molecules expressed by carotid bodies, and which display
some type of modulation of carotid body signaling, include dopamine, histamine,
adenosine, adenosine triphosphate (ATP) and acetylcholine (ACh).
During chemoexcitation, dopamine is released from type-I cells following
increases in intracellular Ca2+ (Gonzalez et al., 1994; Iturriaga et al., 1996). The D2
dopamine receptor is the principal form expressed in type-I cells (Gauda, 2002).
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Dopamine signaling is considered to exert inhibitory action on the chemoreflex by acting
at pre- and post-synaptic sites. In the cat, basal and hypoxia-mediated CSN activity is
increased upon dopamine receptor antagonist administration (Gonzalez et al., 1994;
Iturriaga & Alcayaga, 2004; Shirahata et al., 2007). It is therefore believed dopamine is
involved in regulating a negative feedback within carotid bodies inhibiting
neurotransmitter release.
Similarly, histamine is present and released by type-I cells in response to hypoxic
stimuli (Koerner et al., 2004). Additional analysis revealed the presence of histamine
receptor mRNA for the H1, H2 and an isoform of H3 within carotid bodies (Koerner et
al., 2004). Experimental evidence indicates histamine may be a local modulator of
glomus cell activity, most likely acting in an autocrine/paracrine fashion. Histamine
administration to both perfused and superfused cat carotid bodies resulted in increased
frequency of discharge of CSN, whereas application to isolated PG did not alter
frequency of discharge of CSN (Del Rio et al., 2008) which may implicate histamine as a
modulator of carotid body activity rather than a CSN signaling molecule.
Adenosine also possesses the potential to modulate the chemoreceptor reflex,
most likely through autocrine/paracrine influence. It is well known type-I cells possess
adenosine A2A and A2B receptors (Conde et al., 2009; Gauda, 2002; Kobayashi et al.,
2000) though the evidence for A1 receptors remains argumentative. Hypoxia also evokes
adenosine release from type-I cells (Conde & Monteiro, 2004). Adenosine signaling
through A2A receptors acts to decrease inward calcium (Ca2+) currents into the type-I
cells (Kobayashi et al., 2000), indicating adenosine, like dopamine, most likely acts as an
inhibitor of chemoreflex signaling. However, it is well known that exogenous application
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of adenosine serves to increase CSN activity in cats (McQueen & Ribeiro, 1981;
McQueen & Ribeiro, 1983; Runold et al., 1990). Additional studies however have
displayed opposing results to the Kobayashi (2000) study. In fact, the study by Xu et al.
(2006) has indicated adenosine causes depolarization of type-I cells and results in
increased intracellular Ca2+ concentrations via the A2A receptor, indicating adenosine
may in fact potentiate the chemoreflex.
The cases of ATP and ACh are slightly different than the previously discussed
signaling peptides. ATP and ACh show the potential for signaling not only presynaptically in autocrine/paracrine fashion but also post-synaptically. That is, ATP and
ACh show evidence of release from type-I cells and subsequently signaling directly to the
CSN and may be involved in transduction from chemical signal to electrical impulse.
ATP is commonly believed to be a critical excitatory signaler from type-I cells to
the CSN. This notion is strongly supported by studies using co-cultures of type-I cells
juxtaposed with PG neurons. In this situation, in vitro, functional interactions between
type-I cells and PG neurons were re-created (Zhang et al., 2000; Zhong et al., 1997).
Purinergic receptor (P2X) blockers were shown to inhibit the hypoxia-evoked
postsynaptic responses of PG neurons in these culture conditions (Zhang et al., 2000).
Consistent with these results, PG neurons are known to express two isoforms of the
purinergic receptors, P2X2 and P2X3 (Zhang et al., 2000). Not only are these receptors
present in PG neurons, they are localized to afferent nerve terminals with the carotid
body of the rat (Prasad et al., 2001). Further support for ATP signaling post-synaptically
arises from the fact ATP is released from type-I cells exposed to hypoxic conditions in
vitro (Buttigieg & Nurse, 2004).
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ACh also presents a compelling argument to be considered as a main player in
chemoreceptor excitatory responses, though not as convincing as ATP. Early studies
employing nicotinic blockers show partial inhibition of chemosensory discharge of the
CSN in an isolated cat or rat CSN/carotid body preparation (Fitzgerald, 2000; Iturriaga &
Alcayaga, 2004; Zhang et al., 2000; He et al., 2005). Indeed evidence suggests ACh itself
is not responsible for all excitatory carotid body signaling but a combination of ACh and
ATP. In co-culture preparations of PG neurons and type-I cells, application of both
nicotinic and purinergic receptor antagonists is required to completely eliminate
postsynaptic responses (Zhang et al., 2000; Zhang & Nurse 2004; Nurse, 2005).
Additionally, those data also suggest ATP is co-released with ACh, supporting a dual
transmitter system. HPLC studies in vitro have indicated chemosensory stimuli do in fact
promote ACh release from both cat and rabbit carotid bodies (Fitzgerald, 2000; Kim et
al., 2004). There is a good body of evidence implicating ACh as an excitatory transmitter
directly on PG neurons via nicotinic ACh receptors (Zhong & Nurse, 1997; Iturriaga &
Alcayaga, 2004; Fitzgerald, 2000) in addition to modulating type-I cells themselves as
type-I cells also express multiple forms of nicotinic ACh receptors (Fitzgerald, 2000;
Shirahata et al., 2007; Conde & Monteiro, 2006) suggesting an additional role in
autocrine/paracrine signaling.
Finally, the renin-angiotensin system (RAS) has been shown to exist in carotid
body cells (Lam & Leung, 2003). Evidence suggests a local RAS exists within the carotid
body, specifically by the presence of the precursor angiotensinogen and the enzyme
required for conversion to angiotensin II (ANGII), angiotensin-converting enzyme (ACE)
(Lam & Leung, 2003). Additionally, up-regulation of both angiotensinogen and ACE has
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been reported following hypoxia (Lam & Leung, 2003). ANGII action at the carotid body
serves to modulate CSN activity, specifically to increase discharge in a concentrationdependent manner, an effect abolished in the presence of losartan (Allen, 1998; Leung et
al., 2000), a specific angiotensin type-1 receptors (AT1R) blocker. Furthermore, ANGII
acting through the AT1R has also been implicated in sensitization of the peripheral
chemoreceptor reflex following exposure to chronic IH (CIH) (Marcus et al., 2010).
Previous studies have shown that ANGII can modify carotid body afferent discharge
within the CSN in an ex vivo carotid body preparation (Allen, 1998; Leung et al., 2000).
Furthermore, studies have found a high density of ANGII receptors, specifically AT1R,
within carotid body cells (Allen, 1998), and interestingly, chronic hypoxic and CIH
exposure were found to up-regulate AT1R expression (Leung et al., 2000; Marcus et al.,
2010). ANGII signaling in the carotid body was found to increase chemosensitivity of the
chemoreceptor reflex induced by CIH (Marcus et al., 2010). Following CIH exposure,
acute apnea serves to increase SNA to a higher value than in a control, non-CIH exposed
animal. This effect is not evident in the presence of losartan, an AT1R blocker (Marcus et
al., 2010). Additionally, IH was found to increase circulating levels of ANGII (Prabhakar
& Kumar, 2010).
Taken together, these data suggest that carotid body chemo transmission is an
intricate and complex signaling process involving a multitude of signaling molecules
working towards inhibition or excitation of the chemoreflex pathway. Additionally it is
difficult to pinpoint, and probably unlikely that, one transmitter is solely responsible for
direct excitation of the CSN. Additional signaling molecules exist and recent evidence
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would suggest the list of carotid body modulators is far from complete. For full review
of potential transmiters released from carotid body cells see Nurse, 2010.

1.3 Leptin
Coleman (1973) was the first to identify the presence of a circulating element
involved in regulation of body weight. The original studies described that the ob/ob
mouse, presenting with obesity, was due to a lack of this signaling element and that the
obesity observed in the db/db mouse was a result of reduced sensitivity to the element.
This circulating factor, leptin, is a 16 kDa peptide encoded by the obese (ob) gene in mice
and rats and the LEP homolog gene in humans (Zhang et al., 1994). The protein is highly
conserved across species and shows characteristics of the class I cytokine superfamily
(Zhang et al., 1997). Leptin is produced primarily by adipocytes and plasma levels of
leptin are proportional to body fat content (Frederich et al., 1995; Maffei et al., 1995;
Lonnquist et al., 1995), providing the brain with an afferent signal proportional to body
fat levels. Leptin also regulates food intake, functioning as a satiety signal, as well as
increasing energy expenditure via hypothalamic action (Ahima et al., 1996; Jacob et al.,
1997). In lean subjects, leptin tends to circulate at low levels (approximately 5-10 ng/ml)
either attached to binding proteins or in a free-form state (Sinha et al., 1996), however
these levels increase with adiposity. Interestingly, once body fat reaches 30%, circulating
leptin levels increase almost exponentially and levels as high as 98 ng/ml have been
observed (Ostlund et al., 1996). Circulating leptin may access the CNS through the
blood-brain barrier via a saturable and unidirectional system (Banks et al., 1996) which is
believed to involve binding to a short-form leptin receptor (Bjorbaek et al., 1998).
Alternatively, leptin may also exert CNS signaling by production within the brain
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(Wiesner et al., 1999) however the mechanism of action (i.e. autocrine/paracrine or
otherwise) is currently unknown. Acting centrally, leptin promotes weight loss via
promoting satiation and energy expenditure. One mechanism by which energy
expenditure may be increased is by increasing sympathetic nerve activity (SNA) (Mark et
al., 2009; Rahmouni & Morgan, 2007).
Although these metabolic effects are considered the traditional roles of leptin
signaling, leptin may elicit a variety of effects within an organism by signaling either
centrally or directly within a target tissue. Leptin is also involved in other processes
including, but not limited to, modulating inflammatory and immune functions,
reproductive, neuroendocrine, angiogenesis, fatty acid metabolism, glucose homeostasis,
survival and proliferation, plasticity, sensory nerve input, autonomic outflow and
respiration (Bjorbaek & Kahn, 2004; Lago et al., 2007; Malendowicz et al., 2007;
O’Donnell et al., 1999, 2000; Ribatti et al., 2007; Tankersley et al., 1998; Tang, 2008).
Leptin action on a target tissue may be mediated via circulating leptin and thus modulated
by factors affecting leptin production and release from adipocytes or by leptin production
directly from or near the tissue of action as leptin has shown its’ presence not only in
adipocytes but also within bone, mammary gland, stomach, placenta and recently carotid
body glomus cells (Bado et al., 1998; Hoggard et al., 1997, 1998; Porzionato et al.,
2011).

1.3.1 Leptin Production
Leptin gene expression and secretion are influenced by many factors, the primary
influence being body adiposity, specifically white adipose tissue (WAT). Increases in
gene expression and secretion are brought about by overfeeding, consuming a high-fat
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diet, insulin, glucocorticoids and cytokines whereas decreases are manifested by fasting,
testosterone, thyroid hormone as well as cold exposure (Coleman and Hermann, 1999;
Fried et al., 2000). Additionally, the sympathetic nervous system and ANGII have shown
evidence of modulating the production and secretion of leptin.
Activation of the sympathetic nervous system can decrease the amount of WAT
and thus leptin production. Indeed denervation studies in the hamster have suggested
sympathetic innervation directly affects WAT as an increase in fat pad mass was
observed in the denervated side compared to the fat pad with intact sympathetic
innervation (Youngstrom & Bartness, 1998). Fasting is known to increase SNA to WAT,
noticed by increased noradrenaline turnover in WAT, in order to stimulate lipolysis and
liberate fatty acids from energy stores for use as energy (Migliorini et al., 1997) which
would thus decrease circulating leptin levels. It has also been shown using cell cultures
that catecholamines inhibit leptin production in cultured adipocytes (Hardie et al., 1996).
Eliminating peripheral sympathetic innervation chemically can be done by administration
of 6-hydroxydopamine. Using this method, leptin levels are increased during fasting
(Sivitz et al., 1999). These data would suggest that sympathetic activity affects leptin
production and may well have an effect on leptin production in areas receiving
sympathetic inervation besides adipose tissue.
Another method through which leptin production may be mediated is through
ANGII action. It is well-known that the RAS is responsible for producing the vasoactive
hormone ANGII, a hormone increased in the circulation by sympathetic outflow such as
that observed by activation of the peripheral chemoreflex (Prabhakar & Kumar, 2010).
The glomus cells of the carotid body express a myriad of signaling receptors and the
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AT1R is no exception. It has been suggested that ANGII acts through the AT1R in type-I
cells (Allen, 1998), exposing yet another potential modulating hormone exerting an
influence on the peripheral chemoreflex. Evidence indicates the AT1R may mediate Ca2+
release from intracellular stores in type-I cells (Fung et al., 2001) and may therefore be
involved in transmitter release. Furthermore, ANGII effectively increases the release of
leptin from cultured cardiomyocytes and promotes de novo synthesis (Rajapurohitam et
al., 2006) which may play a similar role within type-I cells of the carotid body.

1.3.2 Leptin Receptors
The obese receptor (OB-R), a member of the class I cytokine-receptor family,
possesses an extra-cellular ligand-binding domain, a transmembrane domain and a
cytoplasmic signaling domain. Leptin signals through these receptors of which there are
six known isoforms (a-f) as a result of alternative mRNA splicing from a single gene
(Lee at al., 1996; Wang et al., 1996) with the exception of OB-Re. The differences in
these isoforms lie in the cytoplasmic domain. The short isoforms, OB-Ra,c,d and f
possess shorter cytoplasmic terminals whereas the OB-Re is a secreted and circulating
form of the OB-R and lacks a transmembrane domain (Cottrell & Mercer, 2012). Some of
these short form receptors serve known functions whereas others remain unknown. OBRa functions in transport of leptin across the blood-brain barrier (Golden et al., 1997;
Bjorbaek et al., 1998) and OB-Re binds circulating leptin (Gavrilova et al., 1997; Yang et
al., 2004).
The OB-Rb, often referred to as the long-form leptin receptor due to its extended
intracellular cytoplasmic domain has been implicated in transducing the majority of
leptin’s central signaling effects within the hypothalamus and the NTS (Elmquist et al.,
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1997; Huo et al., 2006, 2007; Wang et al., 1998). Only the OB-Rb is considered capable
of full intracellular signal transduction (Baumann et al., 1996) and thus is the focus of
leptin signaling. In fact, in terms of body weight regulation the OB-Rb is critical as no
phenotypic differences were found between mouse models lacking all OB-R isoforms,
db/db mice lacking only the OB-Rb and ob/ob leptin-deficient mice (Chua et al., 1996;
Tartaglia, 1997).
Upon leptin binding to the ligand-binding domain of the OB-Rb, the receptors act
primarily via the janus kinase/signal transducer and activator of transcription
(JAK/STAT) pathway although other pathways including the mitogen-activated protein
kinase (MAPK) cascade have been known to be stimulated by leptin signaling (Banks et
al., 2000; Elmquist et al., 1997; Fruhbeck, 2006; Hou et al., 2006, 2007; Wang et al.,
1998). Briefly, leptin binding results in JAK2 recruitment and activation which
phosphorylates intracellular tyrosine residues on the OB-Rb. These phosphorylated
tyrosine

residues

allow

association

of

additional

intracellular

proteins

with

phosphotyrosine binding domains which the STAT3 protein possesses. These STAT3
proteins are phosphorylated into the active pSTAT3 form which then dimerize and
translocate to the nucleus where they influence gene transcription (Vaisse et al., 1996)
including transcription of the negative feedback of this signaling cascade suppressor of
cytokine signaling 3 (SOCS3) (Banks et al., 2000). See Figure 1.2 for representative
schematic diagram.

20

Figure 1.2. Representative schematic diagram of OB-Rb signaling through the
JAK/STAT pathway. L - Leptin; P - phosphate group; JAK - Janus Kinase; STAT3 signal transducer and acticator of transcription 3.
Leptin signaling is not solely mediated by the JAK/STAT pathway as its effects
may also be mediated by the activation of extra-cellular signal-related kinase 1/2
(ERK1/2) (Kloek et al., 2002). In fact, the activation of ERK1/2 by leptin has previously
been shown in the hypothalamus where it is known to mediate food intake, body weight
and thermogenic sympathetic outflow (Rahmouni et al., 2009). Additionally, OB-Rb has
been suggested to activate signaling through the phosphoinositide 3-kinase pathway
(Fruhbeck et al., 2006).
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As with any signaling molecule, the expression of the receptor is critical in
determining the sensitivity of a cell or tissue to the peptide. Leptin and its receptors
display a similar interaction as with many other ligand-receptor relationships in that the
availability of the ligand can result in changes in receptor expression. In the ob/ob mouse,
an animal model completely lacking the hormone, a prominent up-regulation of the OB-R
is noticed, an effect which can be counteracted upon administration of exogenous leptin
(Mercer et al., 1997). In a similar manner, conditions inducing lower levels of circulating
leptin (eg. cold exposure, food restriction) result in up-regulation of OB-R within the
hypothalamus (Lin & Huang, 1997; Mercer et al., 1997). Consistent with this interaction,
hyperleptinaemia (such as that seen in the db/db mouse model) results in a decrease in
OB-R expression (Malik & Young, 1996; Wilsey & Scarpace, 2004). This relationship
would likely enhance leptin’s effect in situations where there is low availability of the
peptide and blunt leptin signaling when the ligand is present in excess.

1.3.3 Cardiovascular Effects of Leptin –Peripheral Administration
Leptin infusion in mice has been found to increase SNA to a variety of tissues
including the kidney, brown adipose tissue, hindlimb and adrenal glands (Haynes et al.,
1997). There is also evidence of leptin signaling through afferent nerves resulting in
increases in SNA (Tanida et al., 2000). Although leptin-infusion data in humans are
lacking, in non-human primates leptin has been shown to activate SNA as determined by
plasma catecholamine levels (Tang-Christensen et al., 1999). These increases in SNA
brought about by leptin, particularly on catecholamine levels and SNA to the kidney,
naturally raise questions as to whether leptin then has an effect on blood pressure. The
sympathetic nervous system plays an important role in renal function and if leptin-
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mediated SNA were restricted to the kidney, one may expect arterial pressure to be
increased due to vasoconstriction and tubular sodium reabsorption. In fact,
sympathoexcitation by leptin is followed closely by an increase in arterial pressure
(Dunbar et al., 1997). Intravenous infusion of leptin over 12 days resulting in decreased
food intake resulted in increased arterial pressure and heart rate (Shek et al., 1998).
Additionally, changes in the concentration of leptin within the circulation have been
found to alter the discharge rate of NTS neurons that project to the sympathoexcitatory
sites of the rostral ventrolateral medulla, neurons that were also found to respond to
activation of the peripheral chemoreceptor reflex (Ciriello & Moreau, 2013). Not only do
these leptin-sensitive neurons respond to peripheral chemoreceptor activation, the
response was potentiated by leptin (Ciriello & Moreau, 2013).

1.3.4 Cardiovascular Effects of Leptin – Central Administration
Leptin can exert cardiovascular effects by acting centrally, as has been shown by
studies introducing leptin directly into the CNS. Central administration serves to increase
plasma catecholamines epinephrine and norepinephrine (Satoh et al., 1999). In other
studies, leptin has been found to increase SNA, arterial pressure as well as heart rate and
to inhibit the baroreflex (Arnold et al., 2009; Mark et al., 2009). Leptin may also have a
role in modulating the peripheral chemoreflex at the level of the CNS as microinjection
of leptin into caudal pressor areas of the NTS has been found to potentiate the
sympathetic and blood pressure responses to chemoreflex activation (Ciriello & Moreau,
2012). These cardiovascular effects may not be debilitating under normal homeostatic
conditions, however in conditions of increased circulating leptin, such as in OSA and
obesity, the cardiovascular responses may be detrimental.
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1.3.5 Leptin and Obstructive Sleep Apnea
The hypoxic condition is considered a pro-inflammatory state and thus may have
an effect on a variety of circulating and local cytokines. Leptin is no exception to this and
there is a body of evidence suggesting that circulating leptin is increased in response to
IH. In fact, clinical studies have shown that OSA patients present with increased
circulating levels of leptin compared to BMI-matched controls (Phillips et al., 2000; Ip et
al., 2000). Additionally, OSA patients treated with CPAP show marked reductions in
circulating leptin levels even with no change in BMI (Harsch et al., 2003; Ip et al., 2000).
This would suggest increased peripheral effects of leptin during OSA due to increased
levels in the circulation.

1.3.6 Leptin and Hypoxia
As would be predicted, animals treated with IH show increased circulating leptin
levels compared to their normoxic counterparts (Polotsky et al., 2003), indicating IH may
well play a role in leptin up-regulation and secretion. In fact, Grosfeld and others (2002)
provide direct evidence that hypoxia can up-regulate leptin mRNA expression as well as
increase leptin promoter activity and leptin secretion from cultured adipocytes. The
evidence supporting leptin up-regulation by the hypoxic state, combined with the
previously discussed cardiovascular implications of leptin may provide an avenue in
which cardiovascular comorbidities are brought about in the OSA population.

1.3.7 Leptin and the Carotid Body
Considering the growing body of evidence displaying expression of leptin in a variety
of tissues and the cardiorespiratory implications of leptin signaling, it comes as no
surprise that leptin protein and mRNA are expressed in carotid body type-I cells of both

24

the rat and human (Porzionato et al., 2011). To the date of this writing, there have been
no additional studies investigating the presence of leptin and its receptors in the carotid
body and it is unknown if leptin activates traditional signaling cascades and serves to
activate or inhibit these cells. Additionally, leptin and leptin receptor transcripts may be
altered by hypoxia potentially resulting in changes of signaling strength and ultimately
modulation on the chemoreceptor reflex at the level of the carotid body.

1.3.8 Leptin and Angiotensin II
The relationship between leptin and ANGII has been studied in detail in various
tissues (Cassis et al., 2004; Danser et al., 1999; Haznedaroglu and Buyukasik, 1997;
Haznedaroglu et al., 1996; Hilzendeger et al., 2012). However, data are lacking at the
level of the carotid body. ANGII effects on leptin have been investigated in other tissues
including rat ventricular myocytes where ANGII has been shown to stimulate leptin
production and secretion. Additionally, the hypertrophic effects of ANGII on these cells
were negated upon leptin receptor blockade (Rajapurohitam et al., 2006, 2012). In
cultured rat adipocytes, incubation with ANGII resulted in increased leptin secretion and
mRNA expression whereas inhibition of ANGII using the ACE inhibitor captopril
resulted in decreased leptin secretion (Cassis et al., 2004). Similarly, in the brain, ANGII
signaling through AT1R is required for leptin’s central sympathetic effects (Hilzendeger
et al., 2012). These data may suggest a similar interaction between the carotid body RAS
and leptin signaling in the carotid body.
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1.4 Hypothesis and Specific Objectives
The hypothesis that was tested in these studies was that leptin signals directly in the
carotid body and this signaling will be affected by IH exposure. Leptin may therefore
alter the chemoreceptor reflex by acting directly within the carotid body. A schematic
outlining the general hypothesis can be seen in Figure 1.3. Leptin may exert an effect via
the circulation or its potential release from glomus cells to act in an autocrine/paracrine
fashion or to signal the CSN afferents. Leptin up-regulation, as seen in OSA patients,
may be involved in the hypertension observed in these patients by directly affecting the
signaling of the chemoreceptor reflex.
Specific Objectives:
1. a. Completed in Chapter 2. To determine effect of intermittent hypoxia (IH)
on systemic leptin release.
b. Completed in Chapter 2. To determine whether systemic leptin can signal
in carotid body glomus cells by identifying downstream regulators of
leptin receptor signaling pSTAT3 and immediate early gene expression
fos and fos-related antigen-1 (Fra-1).
2. a. Completed in Chapter 3. To determine the effect of IH on leptin and Ob-Rb
protein levels in glomus cells
b. Completed in Chapter 3. To determine the effect of IH on down-stream
regulators of leptin receptor signaling including pSTAT3 and SOCS3.
3. Completed in Chapter 4. To determine the effect of CIH (7, 95 days) on leptin
and Ob-Rb expression and leptin receptor signaling indicators.

26

4. Completed in Chapter 5. To determine the effect of ACE inhibitor on carotid
body leptin and leptin receptor expression in normoxic and IH conditions
revealing a potential role of angiotensin II in carotid body leptin signaling.
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Figure 1.3. Schematic diagram of overall hypothesis. CSN-carotid sinus nerve; cNTScaudal nucleus of the solitary tract; AMB-nucleus ambiguous; CVLM-caudal
ventrolateral medulla; RVLM-rostral ventrolateral medulla; HR-heart rate; AP-arterial
pressure; IX & X afferents-cranial nerve IX and X afferents.
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Chapter 2

2

Intermittent Hypoxia and Systemic Leptin Administration
Induces pSTAT3 and Fos/Fra-1 in the Carotid Body
2.1 Introduction
Intermittent hypoxia (IH), the repeated episodes of hypoxia followed by reoxygenation, is an experimental model in animals (Fletcher et al., 1992b) used to mimic
obstructive sleep apnea (OSA) (Dempsey et al., 2010). OSA is a common pathological
condition, observed especially within overweight and obese patients (Dempsey et al.,
2010; Young et al., 1993; Yu and Berger, 2011). OSA is characterized by a brief but
repeated collapse of the upper pharyngeal airway throughout the sleep period which in
turn induces a state of chronic IH (Dempsey et al., 2010; Young et al., 1993). Studies
have previously shown that patients with OSA have an increased risk of heart disease,
stroke, myocardial ischemia, and hypertension that may later contribute to increased
mortality in these patients (Dempsey et al., 2010; He et al., 1988; Shamsuzzaman et al.,
2003). Animals exposed to IH also develop an increased arterial pressure that is
dependent on an intact peripheral chemoreceptor reflex (Fletcher et al., 1992a-b). Thus, it
is has been suggested that the resultant hypoxia during OSA and IH activates peripheral
chemoreceptors which in turn drive sympathetic nerve activity that leads to chronic
hypertension (Dempsey et al., 2010; Fletcher et al., 1992b; Peled et al., 1998; Somers et
al., 1995).
Peripheral chemoreceptors are located throughout the circulatory systems and
within specific organs, although those that sense the partial pressure of oxygen (PO2)
within the blood are found predominantly within the carotid bodies located at the
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bifurcation of the internal and external branches of the carotid artery (Heymans et al.,
1930, West 1995). Type-1 glomus cells within the carotid bodies play an integral role in
detecting changes in PO2 by transducing this chemical signal to sensory afferent neurons
within the petrosal (PG) and nodose (NG) ganglia that signal brainstem autonomic reflex
pathways (Fung et al., 2001). Although the evidence is ambiguous with regard to the
transmitter in type-1 glomus cells responsible for the signal transduction of the peripheral
chemoreceptor reflex, dopamine (Gomez-Nino et al., 1990), norepinephrine (GomezNino et al., 1990), acetylcholine (Eyzaguirre &Zapata, 1968), as well as adenosine
triphosphate (Bock, 1980) have been suggested as signaling molecules. Recently, leptin,
a 16 kDa adipokine protein product of the Ob gene, and 4 of its receptor isoforms (Lee et
al., 1996; Wang et al., 1996) have been identified within only type-1 glomus cells of the
carotid bodies (Porzionato et al., 2011).
Leptin is normally secreted by adipocytes in proportion to the amount of body
adiposity (Lonnquist et al., 1995; Caro et al., 1996). Leptin’s primary action is to elicit a
satiety effect, as well as exert an effect on glucose homeostasis, energy expenditure, and
weight loss through the activation of hypothalamic autonomic regulatory systems (Ahima
et al., 1996; Bjørbaek & Kahn, 2004; Jacob et al., 1997; O'Donnell et al., 2000; Shirasaka
et al., 2003). Additionally, leptin has been suggested to modulate respiratory activity
(Tankersley et al., 1998). In ob/ob mice, those with a mutation in the obese gene
encoding leptin, chronic leptin administration restores their rapid breathing pattern
(Tankersley et al., 1998). However, it is worth noting that acute leptin replacement
significantly increases baseline ventilation as well as chemosensitivity during sleep, a
characteristic independent of weight gain (O’Donnell et al., 1999). Leptin microinjection
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into the nucleus of the solitary tract (NTS), the primary site of termination of
chemoreceptor afferent fibers (Ciriello et al., 1981, 1994) also produces respiratory
effects, increasing pulmonary ventilation and respiratory volume as well as enhancing
electrical activity to inspiratory muscles (Inyushkin et al., 2009). Furthermore, injections
of leptin within NTS potentiate the cardiovascular responses during activation of the
chemoreceptor reflex (Ciriello and Moreau, 2011), likely by altering the activity of the
downstream regulator phosphorylated signal transducer and activator of transcription 3
(pSTAT3) (Hubschle et al., 2001). Peripheral administration of leptin has been shown to
induce both pSTAT3 and fos-like immunoreactivity within the hypothalamus and within
NTS (Elmquist et al., 1997; Huo et al., 2006, 2007; Wang et al., 1998).
In this study, experiments were done to determine whether carotid body glomus
cells expressing the Ob-Rb can be functionally activated in vivo. The first series of
experiments was done to determine whether carotid body glomus cells identified
immunohistochemically by the presence of tyrosine hydoxylase (TH) (Bolme et al.,
1977) and that expressed the Ob-Rb were activated by IH. This was done by examining
immunohistochemically the immediate early gene products fos- and fos-related antigen-1
(Fra-1)-like proteins within these cells. The immediate early gene c-fos has been
implicated as one of the third messengers in the intracellular signal transduction pathway
in a variety of cells (Morgan et al., 1987; Morgan & Curran, 1990). The basal expression
of the fos protein is relatively low, but it can be induced rapidly and transiently by growth
factors, neurotransmitters, second messengers, or membrane depolarization (Morgan et
al., 1987; Morgan and Curran, 1990; Sagar et al., 1988; Solano-Flores et al., 1997). On
the other hand, Fra-1 is one of the transcription factor complex activator protein-1 that
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plays a central role in regulating gene transcription in several biological processes. The
activator protein-1 is made up of a variety of dimers composed of members of the fos and
jun proteins, and the activating transcription factor families of proteins (Curran & Franza,
1988; Rauscher et al., 1988; Shaulian & Karin, 2002). The fos and Fra-1
immunohistochemical techniques have been used for the detection of changes in cellular
activity during the application of a variety of specific physiological, chemical, and
electrical stimuli (Hochstenbach et al., 1993; Morgan et al., 1987; Morgan and Curran,
1990; Sagar et al., 1988; Solano-Flores et al., 1997). However, while fos expression
peaks within about 2 h after the stimulus and returns to baseline within 6-8 h, other
immediate early gene proteins such as Fra-1 are also synthesized soon after their
induction, but persist mainly in the cell nucleus for longer periods of time, which range
from about 1-2 days to several weeks. Additionally, as it would be expected that
activation of the carotid bodies would lead to increased activity within the sensory
neurons, the PG and NG were processed for fos- and Fra-1-like immunoreactivity. The
carotid bodies and associated ganglia of animals exposed to IH were further processed
immunohistochemically for the expression of pSTAT3. The effects of leptin are mediated
by receptors following the induction of a central signaling pathway that involves
activation of signal transducer and activator-3 (Vaisse et al., 1996)
In the second series, to determine whether the pSTAT3 activity during IH was
possibly related to changes in circulating levels of leptin, plasma levels of leptin were
measured in both IH and normoxia exposed animals. As leptin levels were found to be
elevated during IH, the effect of intravenous injections of leptin on fos-, Fra-1 and
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pSTAT3-like immunoreactivity was determined in the carotid bodies and associated
ganglia.
These studies were based on the hypothesis that cells within the carotid bodies
expressing the Ob-Rb would express pSTAT3, fos- and Fra-1-like proteins during both
IH and leptin administration.

2.2 Methods
General Animal Procedures: Experiments were done in male Sprague-Dawley rats
(300–500g; Charles River Canada, St. Constant, Canada). All animals were housed under
controlled conditions under a 12h light/dark cycle. Food and water was available ad
libitum. All experimental procedures were done in accordance with the guidelines on the
use and care of laboratory animals as set by the Canadian Council on Animal Care and
approved by the Animal Care Committee at the University of Western Ontario.
Induction of IH: IH (n=11) or normoxia (n=9) was induced in animals after placing them
into custom made cylindrical plexiglass tubes inside an airtight plexiglass chamber. The
chamber was attached to computer-controlled solenoid valves responsible for regulating
the inflow of either pressurized room air (21% O2) or 100% medical N2. The solenoid
valves were connected to a computerized timer system that allowed for the control of a
total hypoxic (100% medical N2) stimulus delivery of 80 s followed by a normoxic (21%
O2) time of 100 s, for a total continuous repetitive cycle period of 8 h. Additionally, the
controller, attached to detectors for O2 and CO2 within the chamber, was set at a O2 level
of 6.5-7% and CO2 level of 0.1% under isobaric conditions at all times during the
delivery of the hypoxic stimulus and recovery phase. Animals were also run
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simultaneously in a similar adjacent chamber through which only room air (21% O2;
normoxia) was used for the gas exchange in isobaric conditions for an 8 h period.
Leptin ELISA: Measurement of plasma levels of leptin were made immediately after the
exposure of the animals to IH or the normoxic stimulus. Whole blood samples were taken
through a cardiac puncture prior to perfusion of the animal for immunohistochemistry.
Blood samples were drawn into centrifuge tubes containing the anticoagulant
ethylenediaminetetraacetic acid (EDTA; 7%; 10 µl EDTA/1 ml blood; Sigma, St. Louis,
Missouri, USA) and kept on ice. Blood samples were then centrifuged at 10,000 g for 10
min at 4°C, and the plasma was immediately removed and stored at -80°C for later leptin
analysis. Plasma was aliquoted and leptin was measured using a TiterZyme enzyme
immunometric assay kit (Enzo Life Sciences (ADI-900-015A; Farmingdale, New York,
USA)). Samples were diluted 1:4 and assayed in duplicate according to the
manufacturer’s instruction. The recovery is 99% at a known leptin concentration of 2700
pg/ml, 86% at a known leptin concentration of 900 pg/ml and 97% at a known leptin
concentration of 300 pg/ml (Enzo Life Sciences, Farmingdale, New York, USA). The
sensitivity of the assay is 67.2 pg/ml at the 95% confidence limits (Enzo Life Sciences,
Farmingdale, New York, USA). The cross-reactivity of the recombinant leptin antiserum
is 100% with rat leptin whereas it does not cross-react with mouse or human leptin (Enzo
Life Sciences, Farmingdale, New York, USA). The intra-assay coefficient of variation
was 2.5%, and the inter-assay coefficient of variation was 4.1%. The assay was read
using a SpectraMax M5 plate reader (Molecular Devices; Sunnyvale, California, USA).
Intravenous Leptin Administration: On the day of the experiments, the animals were
anesthetized with alpha-chloralose (40 mg/kg i.v. initially, and supplemented by
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additional doses of 10 mg/kg every 30 min) after induction with equithesin (0.3 mL/100
g, i.p.). Body temperature was maintained at 36-37˚C by a heating pad (model K-20-C;
American Hospital Supply, Cincinnati, Ohio, USA). Prior to surgery, 0.2 mL of lidocaine
was injected into the neck region where the right jugular vein was to be isolated and
cannulated with a polyethylene catheter-50 (Clay Adams, Parsippany, New Jersey, USA).
This jugular vein cannula was used for administration of anesthetic, leptin and the saline
vehicle. Animals were allowed to recover for a period of 2 h in a dark and quiet room
immediately after the jugular vein cannulation. The animals then received three 0.1 mL
injections (at 0, 30 and 60 min) of either leptin (50 ng/0.1 mL, n=3; 200 ng/0.1 mL, n=3)
or physiological saline (0.9%, n=1) while remaining in the dark under silent conditions.
Immunohistochemistry: In the chronic studies, immediately after the application of the
8h IH or the normoxic (control animals) stimuli the animals were anesthetized with 0.3
ml/100g equithesin and perfused transcardially using 500 mL ice-cold phosphate buffered
saline (PBS; 0.01M, pH 7.4) followed by Zamboni’s fixative containing 2%
paraformaldehyde in 0.1 M PBS and 15% saturated picric acid (Solano-Flores et al.,
1997). In the acute studies, 90 min after the initial intravenous injection of either leptin or
the saline vehicle the animals were similarly perfused transcardially with PBS followed
by the Zamboni fixative.
The carotid arteries on both sides at their bifurcations, along with the carotid
bodies, the PG and NG and adjacent ganglia (jugular and superior cervical ganglia) were
removed and stored overnight in Zamboni’s fixative at 4 ºC. The following day the
tissues were gradually dehydrated through a series of alcohols, and placed in xylene
followed by paraffin wax. Serial transverse sections were cut at 6 µm on a RM 2155
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microtome (Leica Microsystems Inc., Buffalo Grove, Illinois, USA) floated in a warm
water bath and mounted on double-gelatinized glass microscope slides and placed on a
slide warmer. Tissue sections were later de-paraffinized in xylene and rehydrated using
graded alcohol solutions. For each animal, 1 in every 5 slides was stained with thionin to
identify the region of the carotid body, ganglia and blood vessels. Adjacent deparaffinized sections were rinsed in PBS and endogenous peroxidase activity was
blocked using 1% hydrogen peroxide in PBS for 10 min at room temperature and
processed for tyrosine hydroxylase (TH) -like immunoreactivity to identify the carotid
body glomus cells. In brief, sections were rinsed twice in PBS before being placed in 5%
normal goat serum (Vectastain Elite Kit, Vector Laboratories, Burlingame, California,
USA) in PBS containing 0.3% Triton X-100 for 30 min. The sections were then rinsed in
PBS and placed for overnight (12h) in primary polyclonal rabbit anti-TH (Cat.# ab112;
Abcam, Cambridge, Massachusetts, USA) diluted 1:1000 in PBS/0.3% Triton X-100 at
room temperature.

Following two rinses in PBS, the sections were placed in goat

biotinylated anti-rabbit IgG (Vectastain Elite Kit, Vector Laboratories, Burlingame,
California, USA) diluted 1:200 in PBS/0.3% Triton X-100 for 1 h.
Tissue sections immediately adjacent to those immunostained for TH were
processed to visualize Ob-Rb immunoreactivity. These tissue sections underwent an
antigen-retrieval protocol using a citrate buffer (10 mM sodium citrate/0.05% Tween; pH
6.0) heated to 90-95ºC in a microwave for 15 min. Slides were then rinsed and
endogenous peroxidase activity was inhibited by exposing the sections to a 1% hydrogen
peroxide solution for 10 min. Sections were washed in PBS and allowed to incubate
overnight at room temperature in affinity purified chicken anti-Ob-Rb (Cat. # CH14104,
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LepRb/OBRb; Neuromics Inc., Edina, Minnesota, USA) antiserum (1:1000 in PBS/0.3%
Triton-X 100 and 4% normal goat serum). Following two rinses in PBS, the sections
were then placed in goat biotinylated anti-chicken IgY (Vectastain Elite Kit, Vector
Laboratories, Burlingame, California, USA) diluted 1:200 in PBS/0.3% Triton X-100 for
1 h. Similarly, to visualize pSTAT3 immunolabeling, additional sections also underwent
an antigen-retrieval protocol using a citrate buffer as described above. Slides were then
rinsed and endogenous peroxidase blocking was done using a solution of 1% NaOH and
1% hydrogen peroxide. Sections were then exposed to 0.3% glycine in distilled water (10
min) and 0.6% SDS in distilled water (15 min) to ensure permeability of the tissue.
Following a PBS rinse, sections were exposed to polyclonal rabbit pSTAT3 primary
antibody (anti-pSTAT3; Cat. # 9145, phospho-stat3 (Tyr705) (D3A7) XP; Cell Signaling
Technology Inc., Beverly, Massachusetts, USA).
Finally, additional tissue sections adjacent to those immunostained for TH and
Ob-Rb were processed for fos- or Fra-1 like immunoreactivity as described above.
However, the sections were placed overnight (12h) in primary polyclonal rabbit anti-fos
(Cat. # sc52; Santa Cruz Biotechnology Inc.; Santa Cruz, California, USA) or primary
polyclonal mouse anti-Fra-1 (Cat. # sc253; Santa Cruz Biotechnology Inc.; Santa Cruz,
California, USA) diluted 1:2500 in PBS/0.3% Triton X-100 at room temperature.
Following exposure of the tissue to the secondary antibodies, sections for either
TH, Ob-Rb, pSTAT3, fos, or Fra-1 were rinsed twice in PBS and acetate buffer (pH 5.5),
and

immersed for 40 min in

a solution of 0.05%

3,3’-diaminobenzidine

tetrahydrochloride (DAB; Sigma, St. Louis, Missouri, USA), or a solution of 0.05% of
DAB with 0.01% nickel ammonium sulfate in acetate buffer, containing 0.2% β-D
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glucose, 0.004% ammonium chloride and 0.001% glucose oxidase in PB for 10 min. The
slides with sections were rinsed in acetate buffer, washed in PBS, air dried overnight,
dehydrated in a graded series of alcohol, cleared in xylene and cover-glassed using DPX
mounting medium.
Two types of controls for immunoreactivity were used: omission of the primary
antibody and the preabsorption of the antisera with an excess of respective antigen. Under
these conditions no immunoreactivity was demonstrated within the tissue sections. The
antisera employed in these studies have been already been characterized for specificity
(Chandrasekar and Dreyer, 2010; Tripathi and McTigue, 2008; Liu and Guthrie, 2011;
Logullo et al., 2011).
Immunofluorescence: Additional de-paraffinized sections from IH-exposed animals and
leptin-injected animals (200 ng/0.1ml) were rinsed in PBS and processed for doubleimmunofluorescence for Ob-Rb and Fra-1. Sections underwent antigen-retrieval as
previously described previously and then rinsed in PBS before being placed in 5%
normal goat serum (Vectastain Elite Kit, Vector Laboratories, Burlingame, California,
USA) in PBS containing 0.3% Triton X-100 for 30 min. The sections were later rinsed in
PBS and placed overnight (12 h) in primary polyclonal rabbit anti-Fra-1 diluted 1:1000 in
PBS/0.3% Triton X-100 at room temperature. Sections were then rinsed in PBS and
immersed

in

Streptavidin

Texas

Red

(Code:

RPN1233;

GE

Healthcare,

Buckinghamshire, England) diluted 1:100 for 1 h. Following PBS rinses, sections were
exposed to avidin solution for 15 min followed by biotin solution for 15 min
(Avidin/Biotin blocking kit, Cat. # SP-2001; Vector Laboratories, Burlingame,
California, USA) to block non-specific binding. Sections were rinsed in PBS and
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incubated overnight at room temperature in affinity purified chicken anti-Ob-Rb
antiserum (1:1000 in PBS/0.3% Triton-X 100 and 4% normal goat serum). Following
PBS washes, the sections were placed in goat biotinylated anti-chicken IgY (Vectastain
Elite Kit, Vector Laboratories, Burlingame, California, USA) diluted 1:200 in PBS/0.3%
Triton X-100 for 1 h. Sections were rinsed in PBS and placed in Streptavidin Alexafluor488 (Cat. # S11223; Invitrogen, Burlington, Ontario, Canada) diluted 1:100 for 1 h.
Following PBS rinses, sections were placed in 100% ethanol containing 5% glacial acetic
acid on dry ice for 10 min. Sections were immediately cover-glassed using Fluoromount
mountant.
Histological Analysis: Cells containing TH-, Ob-Rb-, pSTAT3-, fos-, or Fra-1-like
immunoreactivity were identified on sections throughout the region of the carotid body
and ganglia using bright-field or fluorescence microscopy (Leica Diaplan, Leica
Microsystems Inc., Concord, Ontario, Canada). Digital images of these cells were
obtained with a Nikon DS-Fil camera and NIS Elements Basic Research 3.0 software
(Nikon Canada, Mississauga, Ontario, Canada).
Statistical Analysis: Plasma leptin levels in the IH and normoxia exposed animals were
compared using a one-tailed, unpaired Student t-test. A p-value of < 0.05 was taken as
statistically significant.

2.3 Results
Effect of IH on plasma leptin: As shown in Figure 2.1, exposure of animals to IH for an
8 h period significantly (p < 0.05) raised the level of plasma leptin compared to animals
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exposed to normoxic conditions. IH increased circulating leptin (8.78 ± 1.47 ng/mL)
more than two-fold above that found in control animals (3.74 ± 0.17 ng/mL).

*

Figure 2.1. Bar chart showing the effect of IH (hypoxia) on plasma levels of leptin.
Means ± S.E.; * p < 0.05. n=6.
Ob-Rb expression in rat carotid bodies: As previously described (Porzionato et al.,
2011), Figure 2.2 shows that cells within the carotid body (Fig. 2.2a) express TH
immunoreactivity (Fig. 2.2b). Additionally, carotid body cells express the Ob-Rb (Fig.
2.2c) in an overlapping distribution with cells that also expressed the enzyme TH,
indicating that they were likely type-1 glomus cells (Bolme et al., 1977; Porzionato et al.,
2011). Therefore, we have used these observations in the remaining experiments to
determine whether carotid body glomus cells expressed pSTAT3, fos-, or Fra-1 -like
immunoreactivity during CIH and intravenous injections of leptin.
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pSTAT3-, fos-, and Fra-1 - like immunoreactivity in the carotid body after IH or
normoxia: The finding of increased circulating levels of leptin during IH (Fig. 2.1)
suggested that leptin may exert an effect on Ob-Rb expressing cells (Fig. 2.2) in the
carotid body. Figure 2.3 shows the carotid body taken from a normoxic control animal. In
these normoxic control conditions, cells within the carotid body express neither pSTAT3(Fig. 2.3c), fos- nor Fra-1 (Fig. 2.3d) -like immunoreactivity. In contrast, Figures 2.4 and
2.5 show that after exposure of the animal to IH, carotid body cells express pSTAT3(Fig. 2.4c-d), fos- and Fra-1 (Fig. 2.4d-e; Fig. 2.5a-c)- like immunoreactivity.
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Figure 2.2. Bright-field photomicrographs through the region of the carotid body (CB)
stained with thionin (a), or for TH- (b) and Ob-Rb (c) - like immunoreactivity. The
distance between sections shown is 18 µm. Note that many cells within the carotid body
stain for TH (b), which has been previously used for identification of glomus cells within
the carotid body. Ob-Rb immunoreactivity appears to have an overlapping distribution.
Calibrations mark in (a) represents 100 µm and applies to (a-c).
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Figure 2.3. A series of bright-field photomicrographs through the region of the carotid
body (CB) 18 µm apart stained with thionin (a), or for TH- (b), pSTAT3- (c), and Fra-1(d) like immunoreactivity taken from an animal exposed to normoxia (control). Note the
lack of both pSTAT3 and Fra-1 immunoreactivity in the CB. Calibrations mark in (a)
represents 100 µm and applies to (a-d).
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Figure 2.4. Bright-field photomicrographs taken through the region of the carotid body
(CB) from an animal exposed to IH. The distance between each section shown is about
18 µm. (a), Nissl; stained section showing morphology of the CB and its proximity to the
internal

carotid

artery

(Int

CA);

(b),

TH-immunoreactivity;

(c-d),

pSTAT3

immunoreactivity. Inset in (c) is shown at greater magnification in (d); (e-f), Fra-1
immunoreactivity. Inset in (e) is shown at greater magnification in (f). Note the
overlapping distribution of TH, pSTAT3 and Fra-1 immunoreactivity within the CB.
Calibration mark in (a) represents 100 µm and applies to (b, c and e), and represents 25
µm in (d and f).
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Figure 2.5. Fluorescent photomicrographs showing carotid body cells immunoreactive to
Ob-Rb and Fra-1 following IH (a-c) and after injection of 200 ng/0.1 mL (iv) leptin (d-f).
Calibration mark in (a) represents 100 µm and applies (a-f).
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pSTAT3, fos-, and Fra-1 - like immunoreactivity in the carotid body after leptin
injection: To determine whether circulating levels of leptin contributed to the changes in
expression of pSTAT3, fos or Fra-1 in carotid body cells during IH, the effect of
intravenously administering two different dosages of leptin on these proteins was
examined within the carotid body. As shown in Figure 2.6, the low dosage of leptin did
not induce either fos- or Fra-1 (Fig. 2.6d) -like immunoreactivity within carotid body
cells (Fig. 2.6). However, a few cells express pSTAT3-like immunoreactivity (Fig. 2.6c).
In contrast, as shown in Figures 2.5 and 2.7, injections of the higher dose of leptin
induced pSTAT3- (Fig. 2.7c), fos-, and Fra-1 (Fig. 2.5 d-f; Fig. 2.7d) -like
immunoreactivity within carotid body cells that had a similar distribution to CB cells that
expressed the Ob-Rb (Fig. 2.7b). Figures 2.7e and f demonstrate that in the same animal,
adjacent control stained sections in which the primary antibody was omitted show no
immunoreactivity to either pSTAT3 or Fra-1.
Control intravenous injections of the vehicle saline, in the same volume as that
used for injections of leptin, did not induce changes in either pSTAT3 (Fig. 2.8c), fos
(Fig. 2.8d), or Fra-1.
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Figure 2.6. A series of bright-field photomicrographs of adjacent sections (18 µm apart)
taken through the region of the carotid body (CB; a) showing the distribution of TH- (b),
pSTAT3-(c), Fra-1- (d) like immunoreactivity, from an animal that received three 50
ng/0.1 mL injections of leptin every 30 min over a 90 min period. Note the CB lacks
labelling for pSTAT3 and Fra-1. IntCA, lumen of internal carotid artery. Calibrations
mark in (a) represents 100 µm and applies to (a -d).
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Figure 2.7. Bright-field photomicrographs of adjacent sections (18 µm apart) taken
through the region of the carotid body (CB; a) showing the distribution of Ob-Rb- (b),
pSTAT3-(c and e), Fra-1- (d and f), from an animal that received three 200 ng/0.1 mL
injections of leptin every 30 min over a 90 min period. Panel (a) is a Nissl stained
section of CB. Panels (e and f) are control sections processed immunohistochemically for
pSTAT3 (e) and Fra-1 (f) following omission of the primary antibody. Note the lack of
immunoreactivity in (e) or (f) compared to (c) and (d). Also note the overlapping
distribution of Ob-Rb, pSTAT3 and Fra-1 in the CB. Calibrations mark in (a) represents
100 µm and applies to (a -f).
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Figure 2.8. Bright-field photomicrographs of adjacent sections (18 µm apart) taken
through the region of the carotid body (CB; a) showing the distribution of TH- (b),
pSTAT3-(c), and fos (d) immunoreactivity in an animal that received three saline
injections of equal volume to those for leptin (0.1 mL) over 30 min over a 90 min period.
Note that saline injections do not induce either pSTAT3 (c), fos (d) or Fra-1 (not shown)
immunoreactivity in the CB. IntCA, lumen of internal carotid artery; ExtCA, lumen of
external carotid artery. Calibration mark in (a) represents 150 µm and represents 100 µm
in (b-d).
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fos-, Fra-1- and pSTAT3-like immunoreactivity in the nodose/petrosal complex after
intravenous leptin injections:
The finding that intravenous injections of leptin induced pSTAT3, fos and Fra-1
immunoreactivity in the carotid body suggested that sensory neurons mediating the
chemoreceptor information may also in turn be activated. To test this hypothesis, the PG,
NG and other adjacent ganglia near the carotid body were examined for pSTAT3, fos or
Fra-1 activity after leptin injections. Figure 2.9 shows a series of adjacent 6 µm sections
stained for Nissl substance (Fig. 2.9a), and for TH- (Fig. 2.9b), Ob-Rb- (Fig. 2.9d and g),
fos- (Fig. 2.9e and f), and Fra-1 (Fig. 2.9f and i) -like immunoreactivity within the PG.
PG and NG afferent neurons contained Ob-Rb immunoreactivity (Fig. 2.9d and g), and
fos and Fra-1 labeling (Fig. 2.9e and h and Fig. 2.9f and i, respectively). An unexpected
finding was that in all animals studied, regardless if they were exposed to normoxia, IH,
or injected with leptin or saline, the PG (Fig. 2.9b) and NG displayed very few TH
labeled cells, while the superior cervical ganglion, as expected, contained many TH
labeled neurons.
In addition to neurons within the PG and NG that contained Ob-Rb labeling, vagal
nerve (Fig. 2.10b) and carotid sinus nerve fibers (Fig. 2.10c) were found to contain ObRb immunoreactivity. Fibers immunoreactive to Ob-Rb were also observed coursing
through the carotid body among Ob-Rb labeled cells (Fig. 2.10d), and through the PG
and NG (Figs. 2.10e-f). Furthermore, a small number of neurons were found within the
proximal pole of the jugular ganglion which also contained Fra-1- like immunoreactivity
(Fig. 2.11).
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A small number of fibers were also found that contained pSTAT3-like
immunoreactivity (Fig. 2.12) within the carotid body of both the IH and the higher dose
of leptin injected animals. These labeled fibers were seen to extend from labelled cells,
and in some cases appeared to connect pSTAT3 labelled cells (Fig. 2.12c).
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Figure 2.9. Bright-field photomicrographs taken through the petrosal ganglion (PG; a-b
and d-i) showing neurons expressing TH (b), Ob-Rb (d and g), fos (e and h) and Fra-1 (f
and i) immunoreactivity in an animal that received three 200 ng/0.1 mL injections of
leptin every 30 min over a 90 min period.

Note that PG neurons express Ob-Rb

immunoreactivity (d and g) and leptin injections induce both fos (e and h), and Fra-1 (f
and i) immunoreactivity within PG neurons (arrows). Insets in (d-f) correspond to
photomicrographs (g-i, respectively) at higher magnification. Note also the small number
of PG neurons that express TH (b) while all neurons within the superior cervical ganglion
(SCG) express TH (c). VN, vagus nerve. Calibrations mark in (a) represents 100 µm and
applies to (a -f) and represents 25 µm in (g-i).
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Figure 2.10. Bright-field photomicrographs taken through the region of the carotid body
(CB) (a-d) and the petrosal (PG)/nodose (NG) complex showing the distribution of ObRb immunoreactivity within nerve fibers. (a), thionin stained section showing
cytoarchitecture of the CB region. VN, vagus nerve; CA, lumen of carotid artery. Inset in
(a) is shown in (b) which is taken from an adjacent section 6 µm away; (b) Ob-Rb
labeling within vagal nerve fibers (arrows); (c) shows Ob-Rb immunoreactivity within
the CB and the carotid sinus nerve (CSN; arrow); and (d) Ob-Rb immunoreactivity in the
CB. Note fibers expressing the Ob-Rb (arrows) coursing through the CB; (e) Ob-Rb
immunoreactivity in PG neurons and the adjacent vagus nerve (VN) and
glossopharyngeal nerve (arrow); (f) Ob-Rb expressing neurons and fibers (arrow) within
the NG. Calibration mark in (a) represents 100 µm and represents 25 µm in (b-f).
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Figure 2.11. A series of adjacent bright-field photomicrographs (18 µm apart) through
the jugular ganglion (JG) from an animal that received three 200 ng/mL injections of
leptin over 30 min over a 90 min period. (a) thionin stained; (b) pSTAT3
immunoreactivity; (c) Fra-1 immunoreactivity. Note that leptin injections induce both
pSTAT3 and Fra-1 express in the JG. Calibration mark in (a) represents 100 µm.
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Figure 2.12. Bright-field photomicrographs taken through the region of the carotid body
from an animal exposed to IH showing pSTAT3 immunoreactivity (a-c) within cells and
fibers coursing through the carotid body (arrows). Calibrations mark in (a) represents 25
µm and applies to (a-c).
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2.4 Discussion
This study has provided the first direct evidence showing that cells within the
carotid body that express the Ob-Rb are functionally activated during IH and following
intravenous administration of leptin. Both IH and leptin injections were found to induce
the expression of pSTAT3, fos and Fra-1immunoreactivity. IH was also shown to result
in a greater than two fold increase in circulating levels of leptin. Additionally, sensory
neurons were found within the PG and NG that not only expressed the Ob-Rb, but were
also activated in response to intravenous injections of leptin. Furthermore, afferent fibers
within the vagus and carotid sinus nerves were observed to express the Ob-Rb. Taken
together, these observations suggest that leptin may exert an effect on the peripheral
chemoreceptors and their afferent pathway resulting in a modulation of the cardiorespiratory responses induced by IH both at the level of carotid body glomus cell and at
the level of the nucleus of the solitary tract, the primary site of termination of
chemoreceptor afferent fibers (Ciriello et al., 1981, 1994).
The finding that carotid body glomus cells express the Ob-Rb is in agreement
with an earlier study (Porzionato et al., 2011). In addition, on the basis of their finding
that carotid body cells also contained leptin (Porzionato et al., 2011), these authors
suggested that leptin produced by the glomus cells may act in an autocrine/paracrine
fashion to modulate their function and thus, the chemoreceptor reflex. This study has now
shown that neurons within both the PG and NG also express the Ob-Rb. Although the
function of these neurons is not known, the finding that a number of afferent axons in
both the carotid sinus and vagus nerves that also express the Ob-Rb suggest that leptin
may act presynaptically on both axons within the carotid body and the nucleus of the
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solitary tract to influence transmission of chemoreceptor origin. Thus, a plausible
explanation for the finding of PG and NG neurons expressing the Ob-Rb may be that
these receptors are produced in the ganglion cells and transported to their terminal
endings. This would not be unlike the production of angiotensin II receptors within NG
cells that are transported to presynaptic sites in the nucleus of the solitary tract (Diz et al.,
1986; Healy et al., 1989, Lewis et al., 1986). In support of this suggestion, neurons within
the ganglia do not express any significant quantity of pSTAT3, either in animals exposed
to IH or those injected with leptin. This finding indicates that these receptors are not
activated by systemic leptin, even though pSTAT3 is induced in carotid body cells, or as
previously reported within the nucleus of the solitary tract (Elmquist et al., 1997; Huo et
al., 2006, 2007; Wang et al., 1998). However, the possibility cannot be eliminated that
the specific blood brain barrier around ganglion neurons may not allow ready access by
leptin to these Ob-Rb receptors. The finding that both afferent fibers and neurons in the
PG and NG contain Ob-Rb is consistent with the observation that Ob-Rb labeled axons
are found within the nucleus of the solitary tract (Barnes et al., 2010; Ellacott et al., 2006;
Elmquist et al., 1997; Huo et al., 2006, 2007; Shioda et al., 1998).
It should also be noted that leptin has been suggested to play an important role in
axonal growth (Bouret et al., 2004; Pinto et al., 2004; Valerio et al., 2006). Therefore, an
alternate possibility may be that leptin acting through the Ob-Rb may help maintain the
integrity of axons for transmission in a neuronal system that is chronically active in
detecting changing levels of PO2. This is not considered unreasonable as hypoxia has
been shown to induce plasticity within neural circuits controlling respiration (Nurse et al.,
1994; Ling et al., 2001).
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This study has also provided the first evidence in a rat model of IH that during an
8 h period of exposure to IH circulating levels of leptin are elevated. This finding is
consistent with observations in clinical studies showing that patients with OSA have
higher circulating levels of leptin independent of body weight (Harsch et al., 2003;
Phillips et al., 2000). The source of this leptin is unknown. However, as the plasma levels
measured in this study are not as high as those expected in overweight or obese animals,
it may be suggested that this increase in leptin is due to release from the carotid bodies
themselves in response to the lower PO2 during hypoxia. Carotid body cells have been
shown to contain leptin (Porzionato et al., 2011). Regardless of the source of the leptin, it
was found that IH induced pSTAT3, fos and Fra-1 in carotid body cells. The finding of
pSTAT3 induction is suggestive of a leptin mechanism acting within the carotid body.
STAT3 is phosphorylated upon activation of the JAK2/STAT3 pathway and is thought to
be an important component in the Ob-Rb signal transduction in the nervous system
(Bjørbaek et al., 1997; Hubschle et al., 2001). The suggestion of a leptin mechanism
acting within the carotid body is further supported by the finding that intravenous
injections of leptin induced pSTAT3, fos and Fra-1 within carotid body cells. The
estimated amount of leptin injected in this study to induce pSTAT3 would be about 12.4
ng/mL plasma. This is well within the range of plasma leptin levels measured during IH.
Thus, it was not surprising that no expression of these proteins was found in control
normoxic animals, or in animal injected with saline or the low dose of leptin. It is
calculated that the low dose of leptin used in this study would average in the circulation
to be about 4.3 ng/mL plasma. This level is similar to that found within the plasma in the
normoxic controls.
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The carotid bodies taken from both IH and the higher dose of leptin injected
animals expressed both fos and Fra-1 immunoreactivity. In the IH animals, a greater
expression of Fra-1 compared to fos was observed in the carotid bodies. This was not
unexpected as fos expression is known to peak within about 2 h after the stimulus and
return to baseline within 6-8 h, whereas Fra-1 proteins are also synthesized soon after
their induction, but persist from about 1-2 days to several weeks. On the other hand, fos
and Fra-1 expression appeared not to be different within the animals that received the
higher dose of leptin intravenously and were allowed to survive for only 90 min after the
injection. The finding of activation of the immediate early gene products fos and Fra-1 in
the carotid body cells, combined with the increased expression of pSTAT3 can be
interpreted to indicate that these cells were activated in response to IH, likely through a
leptin dependent mechanism. Activation of these cells would then be expected to affect
the transduction of the chemoreceptor signal.
In addition to the carotid body, neurons within the PG/NG complex which are
known to contain the perikarya of the carotid sinus nerve which relay chemoreceptor
afferent inputs to the NTS, expressed fos and Fra-1 labelling in response to leptin
injections. Additionally, a very small number of neurons expressed pSTAT3. The finding
of fos/Fra-1 neurons is consistent with the interpretation that following leptin injections,
the activation of carotid body glomus cells leads to activation of primary sensory
afferents. However, the functional significance of the observation that a few neurons
expressed pSTAT3 is not known. Similarly, the function of the finding that some axons
within the carotid body expressed pSTAT3 is not known. However, it has been
previously suggested that axonal pSTAT3 may function as retrograde signaling
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transcription factor carrying information to the cell genome (Lee et al., 2004). STAT3 has
been suggested to be involved in maintaining the neurochemical phenotype of the neuron
(Lee et al., 2004; Nawa et al., 1990). STAT3 has also been associated with cellular
protective mechanisms when found outside the central nervous system (Schwaiger et al.,
2000; Suzuki et al., 2001; Wen et al., 2001).
Finally, an unexpected finding was the small number of neurons within the
PG/NG complex that expressed TH. Although it could be argued that the sensitivity of
the immunohistochemical procedure used in this study may have not been sufficient to
detect the TH, this possibility is considered unlikely as the superior cervical ganglia
contained extensive TH labeling, as did the carotid body. Although this finding is
consistent with the small number of neurons identified in the distal end of the PG (Finley
et al., 1992; Ichikawa et al., 1993), most studies indicate that a large number of afferent
neurons from the carotid sinus and body express TH (Katz et al., 1983; Katz and Black,
1986), and that TH labeled neurons is often used as a marker for these afferent neurons
within the ganglia.
In summary, the findings that carotid body glomus cells express the Ob-Rb, and
are activated by circulating leptin suggest that leptin may function in the modulation of
the chemoreceptor reflex. Although it remains to be determined whether the leptin that
exerts its effects on the chemoreceptors is released by carotid body glomus cells or from
adipocytes during IH, these findings suggest that leptin can now exert its effects on
cardio-respiratory reflex pathways not only within the central nervous system at the level
of the first synapse within the nucleus of the solitary tract, but also at the level of the
peripheral receptors. Several recent studies have shown that leptin administration into

60

NTS not only alter cardio-respiratory activity (Arnold et al., 2009; Inyushkin et al., 2009,
Mark et al., 2009), but potentiate the arterial pressure and sympathetic nerve responses to
peripheral chemoreceptor activation (Ciriello and Moreau, 2011). On the basis of these
earlier observations, combined with the findings in this study, it is not unreasonable to
suggest that through leptin dependent mechanisms act at several different levels
throughout the chemoreceptor reflex pathway, and that the autonomic effects associated
with OSA may be exacerbated in obese patients with high circulating levels of leptin.
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Chapter 3

3

Effects of Intermittent Hypoxia on Leptin Signalling in the
Carotid Body
3.1 Introduction
Obstructive sleep apnoea is a pathophysiological disorder commonly observed in
overweight and obese patients that is characterized by brief repetitive collapse of the
upper airway during the sleep cycle (Dempsey et al., 2010). If untreated, obstructive
sleep apnoea increases the risk for the development of cardiovascular disease (He et al.,
1988; Shamsuzzaman et al., 2003; Dempsey et al., 2012). These cardiovascular
comorbidities (heart disease, stroke, myocardial ischaemia, atherosclerosis and
hypertension) have been suggested to contribute later in life to increased mortality within
this population. The cessation in respiration exposes the patient to intermittent hypoxia
(IH), a recurring episodic decrease in blood oxygen saturation.
An animal model of IH has been developed to mimic obstructive sleep apnea
(Fletcher et al., 1992b). In this animal model, IH has been shown to increase sympathetic
nerve activity to different vascular beds, an effect dependent on an intact carotid
chemoreceptor reflex (Fletcher et al., 1992a).
Specialized chemo-sensitive organs occur throughout the vascular system, though
the organs predominantly involved in sensing changes in partial pressures of oxygen
(PO2) within the blood are located bilaterally at the bifurcation of the carotid artery
(Heymans et al., 1930; Nurse, 2005). These carotid bodies contain specific chemosensory
glomus cells responsible for the transducing the low PO2 signal, which in turn activate
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the chemosensory nerve endings of the carotid sinus nerve (Heymans et al., 1930; Nurse
2005). These afferent signals arrive to the nucleus of the solitary tract (Ciriello et al.,
1994) and activate homeostatic adaptations including the respiratory, cardiovascular and
sympathetic nervous systems (Schultz and Li, 2007; Kumar, 2009).
Studies to determine the primary signalling molecule between glomus cells and
carotid body afferent nerves have revealed a number of potential transmitter candidates
(Spyer et al., 2003; Nurse, 2005, 2010; Shirahata et al., 2007) that include dopamine
(Gomez-Nino et al., 1990), acetylcholine (Eyzaguirre and Zapata, 1968), and adenosine
triphosphate (Bock, 1980). Recently, the finding of leptin receptor isoforms expressed
within glomus cells (Porzionato et al., 2011; Messenger et al., 2012), combined with the
observation that increased circulating leptin levels induce the expression of
phosphorylated signal transducer and activator of transcription 3 (pSTAT3) and the
immediate early gene Fra-1 within these glomus cells (Messenger et al., 2012) suggest
that leptin may play an important role in modulating chemosensitivity.
Leptin, the 16 kDa highly conserved protein encoded by the obese gene, is
produced predominantly, but not exclusively by adipocytes (Lonnquist et al., 1995; Caro
et al., 1996). Leptin normally circulates in proportion to body adiposity and normally
plays a critical role in body energy balance (Lonnquist et al., 1995; Caro et al., 1996).
Leptin not only functions as a satiety hormone, but also functions to increase metabolism
and thermogenesis, thus stimulating weight loss (Ahima et al., 1996; Jacob et al., 1997;
O'Donnell et al., 2000; Bjorbaek and Kahn, 2004). In addition, central administration of
leptin has been found to have an effect on the cardiovascular system. Central
administration of leptin has been shown to increase sympathetic nerve activity, blood
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pressure, heart rate and decrease baroreflex sensitivity (Arnold et al., 2009; Mark et al.,
2009). Furthermore, microinjections of leptin into caudal pressor sites in the nucleus of
the solitary tract have been shown to potentiate the arterial pressure and sympathetic
nerve responses to activation of the chemoreceptor reflex (Ciriello and Moreau, 2012).
Furthermore, leptin has also been shown to exert an effect on respiration (Tankersley et
al., 1998). Leptin exerts these physiological effects through the activation of the obese
receptors (Ob-R’s), of which there are six known splice variants (Ob-Ra-f) (Lee at al.,
1996; Wang et al., 1996). The long-form leptin receptor (Ob-Rb) operates via the
JAK2/signal transducer and activator of transcription 3 (STAT3) pathway and has been
implicated in transducing most of leptin’s central signalling effects within the
hypothalamus and the brainstem (Elmquist et al., 1997; Wang et al., 1998; Huo et al.,
2006, 2007).
The finding that circulating levels of leptin are elevated during IH (Messenger et
al., 2012), and that leptin injections into the nucleus of the solitary tract can alter the
chemoreceptor reflex (Ciriello and Moreau, 2012), combined with the observation that
leptin receptors exist within the carotid bodies (Porzionato et al., 2011; Messenger et al.,
2012), suggest that leptin may also act through functional receptors on carotid body
glomus cells to alter chemoreflex sensitivity. However, whether IH or leptin alters leptin
signalling pathways within glomus cells, along with whether local leptin and leptin
receptor (Porzionato et al., 2011; Messenger et al., 2012) expression are affected by
changes in arterial PO2 are not known. Therefore, the present study was done to
determine: (1) whether glomus cells expressing the Ob-Rb also express leptin and
whether these cells are activated during IH or during systemic leptin injections; (2)
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whether IH alters leptin and OB-R expression; (3) whether IH alters the protein
expression of STAT3 and pSTAT3, and suppressor of cytokine signalling 3 (SOCS3),
which binds to JAK2, inhibiting leptin-induced signalling through the STAT3 mechanism
(Bjorbaek et al., 2000); (4) whether IH has an effect on the expression of ERK1/2.

3.2 Methods
General: Experiments were done in male Sprague–Dawley rats (Charles River Canada,
St. Constant, Canada) weighing 300-395 g. All animals were housed under controlled
conditions with a 12 h light/dark cycle. Food and water were available ad libitum. All
experimental procedures were done in accordance with the guidelines on the use and care
of laboratory animals as set by the Canadian Council on Animal Care and approved by
the Animal Care Committee at the University of Western Ontario.
Induction of IH: IH (n = 16) or normoxia (n = 15) was induced in animals as previously
described (Messenger et al., 2012). In brief, animals (one/tube) were placed into custom
made cylindrical plexiglass tubes with a zero-pressure escape valve (11-cm diameter x
33-cm length; volume 3136 cm3) inside an airtight plexiglass chamber which housed four
tubes. The animal was allowed to freely move within each tube. The chamber was
attached to computer-controlled solenoid valves responsible for regulating the inflow of
either pressurized room air (21% O2) or 100% medical N2. The solenoid valves were
connected to a computerized timer system that allowed for the control of a total hypoxic
(100% medical N2) stimulus delivery of 80 s followed by a normoxic (21% O2) time of
100 s, for a total continuous repetitive cycle period of 8 h. Additionally, the controller,
attached to detectors for O2 and CO2 within the chamber, was set at a O2 level of 6.5 %
and CO2 level of 0.1% under isobaric conditions at all times during the delivery of the
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hypoxic stimulus and recovery phase during which O2 returned to 20.9%. A control
(normoxic) set of animals was simultaneously run in a similar adjacent chamber through
which only room air (21% O2; normoxia) was used for the gas exchange in isobaric
conditions for an 8-h period.

Plasma leptin levels: Measurement of plasma levels of leptin were made immediately
after the exposure of the animals to IH or the normoxic stimuli (Messenger et al., 2012).
Whole blood samples were taken through a cardiac puncture prior to perfusion of the
animal for immunohistochemistry or collection of tissues for Western blot analysis.
Blood samples were drawn into centrifuge tubes containing the anticoagulant EDTA
(7%; 10 μL EDTA/1 mL blood; Sigma, St. Louis, Missouri, USA) and kept on ice. Blood
samples were then centrifuged and the plasma was immediately removed and stored at
−80 °C for later leptin analysis using a TiterZyme enzyme immunometric assay kit (Enzo
Life Sciences (ADI-900-015A; Farmingdale, New York, USA) as previously described
(Messenger et al., 2012). The assay was read using a SpectraMax M5 plate reader
(Molecular Devices, Sunnyvale, California, USA).

Intravenous leptin injections: On the day of the experiment, the animals were
anaesthetized with alpha-chloralose (80 mg/kg i.v. initially, and supplemented by
additional doses of 10 mg/kg every 30 min) after induction with equithesin
(0.3 mL/100 g, i.p.). Body temperature was maintained at 36–37 °C by a heating pad
(model K-20-C; American Hospital Supply, Cincinnati, Ohio, USA). Prior to surgery,
0.2 mL of lidocaine was injected into the neck region where the right jugular vein was to
be isolated and cannulated with a polyethylene catheter-50 (Clay Adams, Parsippany,
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New Jersey, USA). This jugular vein cannula was used for administration of anaesthetic,
leptin and the saline vehicle. Animals were allowed to recover for a period of 2 h in a
dark and quiet room immediately after the jugular vein cannulation. The animals then
received three 0.1 mL injections (at 0, 30 and 60 min) of either leptin (50 ng/0.1 mL,
n = 3; 200 ng/0.1 mL, n = 3) or physiological saline (0.9%, n = 3) while remaining in the
dark under silent conditions.

Immunofluorescence: Immediately after the application of the 8-h IH or normoxic
stimuli the animals were anaesthetized with 0.3 mL/100 g equithesin and perfused
transcardially using 500 mL ice-cold phosphate-buffered saline (PBS; 0.01 M, pH 7.4)
followed by 4% paraformaldehyde in 0.1 M PBS. The carotid arteries at their
bifurcations, along with the attached carotid bodies were removed bilaterally, and stored
overnight in Zamboni’s fixative at 4 ºC. The following day the tissues were gradually
dehydrated through a series of alcohols, and placed in xylene followed by paraffin wax.
Serial transverse sections were cut at 6 µm on a RM 2155 microtome (Leica
Microsystems Inc., Buffalo Grove, Illinois, USA), floated in a warm water bath and
mounted on double-gelatinized glass microscope slides and placed on a slide warmer.
Tissue sections were later de-paraffinized in xylene and rehydrated using graded alcohol
solutions. For each animal, one in every five slides was stained with Thionin to identify
the region of the carotid body and blood vessels. Additionally, adjacent sections to those
stained for thionin from the normoxic and IH-exposed animals were rinsed in PBS and
processed for double-immunofluorescence for Ob-Rb and leptin. Sections underwent an
antigen-retrieval protocol using a citrate buffer (10 mM sodium citrate/0.05% Tween; pH
6.0) heated to 90-95ºC in a microwave for 15 min and then were rinsed in PBS before
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being placed in 5% normal goat serum (Vectastain Elite Kit, Cat. # PK6100; Vector
Laboratories, Burlingame, California, USA) in PBS containing 0.3% Triton X-100 for 30
min (Messenger et al., 2012). The sections were later rinsed in PBS and placed overnight
(12 h) into a primary polyclonal rabbit anti-leptin (Cat. # sc843; Santa Cruz
Biotechnology Inc., Santa Cruz, California, USA; 1:1000 in PBS/0.3% Triton X-100) at
room temperature. Sections were then rinsed in PBS and incubated in goat biotinylated
anti-rabbit IgG (Vectastain Elite Kit, Vector Laboratories, Burlingame, California, USA)
diluted 1:500 in PBS/ 0.3% Triton X-100 for 1 h. Following PBS rinses, sections were
placed in Streptavidin Alexafluor-488 (Cat. # S11223; Invitrogen, Burlington, Ontario,
Canada) diluted 1:100 for 1 h. Following PBS rinses, sections were exposed to an avidin
containing solution for 15 min followed by a biotin containing solution for an additional
15 min (Avidin/Biotin blocking kit, Cat. # SP-2001; Vector Laboratories, Burlingame,
California, USA) to block non-specific binding sites. Sections were then rinsed in PBS
and incubated overnight at room temperature in either affinity purified chicken anti-ObRb antiserum (Cat. # CH14104, LepRb/OBRb; Neuromics Inc., Edina, Minnesota, USA)
diluted 1:1000 in PBS/0.3% Triton-X 100 and 5% normal goat serum or primary
polyclonal rabbit anti-Fra-1 (Cat. # sc253; Santa Cruz Biotechnology Inc., Santa Cruz,
California, USA) diluted 1:1000 in PBS/0.3% Triton-X 100 and 5% normal goat serum.
Following PBS washes, the sections were placed in goat biotinylated anti-rabbit IgG
(Vectastain Elite Kit, Vector Laboratories, Burlingame, California, USA) diluted 1:500 in
PBS/ 0.3% Triton X-100 or goat biotinylated anti-chicken IgY (Vectastain Elite Kit,
Vector Laboratories, Burlingame, California, USA) diluted 1:200 in PBS/ 0.3% Triton X100 for 1 h. Sections were rinsed in PBS and placed in Streptavidin Texas Red (Code:
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RPN1233; GE Healthcare, Baie d’Urfe, Quebec, Canada) diluted 1:100 for 1 h.
Following PBS rinses, sections were placed in 100% ethanol containing 5% glacial acetic
acid on dry ice for 10 min. Sections were then immediately cover-glassed using
Fluoromount mountant.
Immunohistochemistry: Tissues were processed as described above with the following
exceptions. Following the antigen retrieval protocol, endogenous peroxidase activity was
blocked by placing tissue sections into 1% hydrogen peroxide for 10 min. Sections were
rinsed in PBS and then placed in 5% normal goat serum (Vectastain Elite Kit, Vector
Laboratories, Burlingame, California, USA) in PBS containing 0.3% Triton X-100 for 30
min. The sections were later rinsed in PBS and placed overnight (12 h) at room
temperature in primary monoclonal rabbit anti-pERK1/2 (1:100, Cat. # 4376S; Cell
Signaling Technology, Danvers, Massachusetts, USA) in PBS/0.3% Triton X-100. After
PBS rinses, sections were incubated in goat biotinylated anti-rabbit IgG (Vectastain Elite
Kit, Vector Laboratories, Burlingame, California, USA) diluted 1:1000 in PBS/ 0.3%
Triton X-100 for 1 h. Sections were rinsed in PBS and placed in an immunoperoxidase
detection system (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame,
California, USA) for 75 min, followed by PBS rinses and immersion of the sections for
40 min into a solution of 0.05% 3,3’-diaminobenzidine tetrahydrochloride (DAB; Sigma,
St. Louis, Missouri, USA). The slides with sections were rinsed in PBS, air dried
overnight, dehydrated in a graded series of alcohol, cleared in xylene and cover-glassed
using DPX mounting medium.
Histological analysis: Cells containing leptin-, Ob-Rb- and Fra-1 and ERK1/2-like
immunofluorescence were identified in carotid body glomus cells using fluorescence
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microscopy (Leica Diaplan). Digital images of these cells were obtained with a Nikon
DS-Fil camera and NIS Elements Basic Research 3.0 software (Nikon Canada,
Mississauga, ON, Canada).
Carotid body protein extracts and immunoblot analysis: Carotid body protein extracts
were obtained following bilateral carotid body excision from the 8 h normoxia- or IHexposed animals. Briefly, carotid bodies (bilaterally) from each animal were snap frozen
and pooled and homogenized in 200 µL of RIPA buffer solution (150 mM NaCl, 1 mM
EDTA, 1% Triton-X 100, 50 mM Tris-HCL at pH of 7.5) with a protease inhibitor
cocktail (Roche Diagnostics, Laval, Quebec, Canada). The homogenate was centrifuged
at 4 °C for 15 min at 2100 rpm. The supernatant was retained and then centrifuged a
second time at 4 °C for 20 min at 13,200 rpm. The resultant supernatant was retained as
the protein preparation. Equal concentrations of extracted proteins normalized by
colorimetric BCA Protein Assay (Pierce Corp., Madison, Wisconsin, USA) were
fractionated in 7.5% polyacrylamide gel and transferred onto a polyvinylidene fluoride
membrane. Blots were probed using polyclonal rabbit anti-leptin (1:1000, Cat. # sc843;
Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), polyclonal rabbit anti-OBR (1:1000, Cat. # OBR12-A; Alpha Diagnostics International Inc., San Antonio, Texas,
USA), affinity purified anti-OB-Rb (1:1000, Cat. # CH14104; Neuromics, Edina,
Minnesota, USA), polyclonal rabbit anti-SOCS3 (1:1000, Cat. # ab16030; Abcam Inc.,
Cambridge, Massachusetts, USA), monoclonal rabbit anti-STAT3 (1:2000, Cat. # 4904S;
Cell Signaling Technology, Danvers, Massachusetts, USA), polyclonal rabbit antipSTAT3 (1:1000, Cat. # 9131S; Cell Signaling Technology, Danvers, Massachusetts,
USA), and monoclonal horseradish peroxidase-conjugated β-actin (1:50000, catalogue
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no. A3854, Sigma-Aldrich, St. Louis, Missouri, USA) diluted in 5% milk-1X Trisbuffered saline-Tween 20 buffer and with horseradish peroxidase conjugated donkey
anti-rabbit IgG or donkey anti-chicken IgG (1:10000, catalogue # 711-035-152 or 703035-155,

respectively;

Jackson

ImmunoResearch

Laboratories,

West

Grove,

Pennsylvania, USA) diluted in 5% milk-1X Tris-buffered saline-Tween 20 buffer as the
secondary antibody. Immunoreactive bands were visualized using an enhanced
chemiluminescence detection system (Millipore Canada Ltd, Toronto, Ontario, Canada).

Statistical analysis: Statistical comparisons between plasma leptin levels and Western
blots of the IH and normoxia exposed animals were made using a one-tailed, unpaired
Student t-test. In all comparisons, a minimum p-value of <0.05 was taken to indicate
statistical significance (GraphPad Prism; GraphPad Software, San Diego, California,
USA).

3.3 Results
Plasma leptin levels during IH: As previously reported (Messenger et al., 2012), IH was
found to significantly increase (p < 0.002) plasma leptin levels approximately 5.9-fold
above those found in the normoxic control animals (Fig. 3.1).
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Figure 3.1. Effects of intermittent hypoxia (IH) upon plasma levels of leptin compared to
levels observed in normoxic controls. Values are means ± S.E.; *p < 0.002. n=6 for each
bar.
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Leptin and Fra-1 co-expression in carotid body: Figure 3.2 shows the effect of IH and
systemic injections of leptin on leptin expression and the expression of the immediate
early gene Fra-1 protein within glomus cells of the carotid body. These cells within the
carotid body express little leptin and no Fra-1 immunofluorescence under normoxic
conditions (Figs. 3.2e, f and 3.3). However, following exposure to IH, carotid body
glomus cells exhibited an increased expression of both leptin (Figs. 3.2 a, c, d and 3.3)
and Fra-1 (Fig. 3.2b). Carotid body expression of leptin was increased (~ 60%) (p <
0.001) after the IH (Fig. 3.3).
Intravenous injections of leptin induced an increased expression of leptin within
the carotid body (Fig. 3.4a). These leptin immunoreactive cells also expressed Fra-1
immunoreactivity (Fig. 3.4b, c). The number of cells and the intensity of the leptin
immunofluorescence appeared greater in those animals receiving the 200-ng injections of
leptin compared to those receiving the 50-ng intravenous injections of leptin, although no
statistical evaluation was used. In contrast, intravenous injections of the same volume of
the vehicle (saline) did not alter leptin or Fra-1 labelling within the carotid body (Fig.
3.4d-f). Additionally, no immunoreactivity for leptin or Fra-1 was found with the carotid
body in the immunohistochemical controls for leptin and fra-1 (Fig. 3.4g, h).
Leptin and OB-Rb co-expression in carotid body: As shown in Figure 3.2(g-i), carotid
body cells expressing leptin also co-expressed the Ob-Rb. In addition, it was found that
IH reduced (~ 10%) (p < 0.002) the protein expression of Ob-Rb within the carotid body
(Fig 3.5a). On the other hand, the expression of the short-form leptin receptor (Ob-R100)
protein (Fig. 3.5b) was significantly increased (~ 35%) (p < 0.03).
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Figure 3.2. Fluorescent photomicrographs showing carotid body cells immunoreactive to
leptin (a, c-e, g, i), Fra-1 (b, f) and Ob-Rb (h-i) following exposure to IH (a–d, g-i) or
normoxia (e-f). Inset in (a) corresponds to (d) at higher magnification showing leptin
immunoreactive glomus cells in the carotid body. Calibration marks indicate 100 μm and
applies to (a-c, e-i) and 15 μm in (d).
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Figure 3.3. Western blots showing the presence of leptin protein within the carotid body.
Note the 1.6-fold increase in leptin protein expression following IH in the carotid body.
*, significantly different from normoxia control animals. p value is indicated. n=5-6.
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Figure 3.4. Fluorescent (a-h) and bright-field (i) photomicrographs of the carotid bodies.
Effect of intravenous leptin injections (200 ng/0.1 mL) on leptin and Fra-1 expression in
the glomus cells. Insets in (a-c) correspond to (i) stained with thionin at higher
magnification. The red arrows in (c) and (i) point to the same glomus cell within the
cluster. The arrows in (a) and (b) point to cell expressing leptin, but not Fra-1
immunoreactivity following injections of leptin intravenously. (d-f) show that
intravenous injections of the same volume of vehicle did not induce leptin or Fra-1
expression the carotid body. (g-h) show the lack of immunoreactivity following omission
of the primary antibody during the immunohistochemical processing of the tissue.
Calibration mark in (a-h) represents 100 μm and calibration mark in (i) represents 15 μm.
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Figure 3.5. Western blots showing the presence of Ob-Rb (a) and Ob-R100 (b) in carotid
bodies after IH. Note that IH significantly (*) decreases the protein level of Ob-Rb (a),
while significantly (*) increasing the protein level of Ob-R100 (b) compared to normoxic
controls (b). p values are indicated. n=5-6.
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Effects of IH and leptin injections on ERK1/2 expression in carotid body: Carotid
body glomus cells under normoxic conditions were found to express no ERK1/2 (Fig.
3.6). However, when exposed to IH, the expression of ERK1/2 immunoreactivity within
the carotid body was increased (Fig. 3.6c). Similarly, intravenous injections of leptin (200
ng) induced ERK1/2 expression within the carotid body (Fig. 3.6d). The increased
ERK1/2 in IH exposed animals was co-expressed within carotid body glomus cells that
expressed the Ob-Rb (Fig. 3.7).
Effects of IH on STAT3, pSTAT3 and SOCS3 in carotid body: As shown in Figure 3.8,
exposure of the animal to IH did not alter STAT3 protein expression within the carotid
body (Fig. 3.8a). However, there was a small but significant (p < 0.002) increase in the
expression of pSTAT3 following IH (Fig. 3.8b). Similarly, IH significantly (~ 10%) (p <
0.001) increased the expression of SOCS3 within the carotid body (Fig. 3.8c).
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Figure 3.6. Bright-field photomicrographs of carotid bodies stained with thionin (a), or
exhibiting ERK1/2 immunoreactivity after exposure to normoxia (b), acute IH (c), and
after intravenous injections of leptin (200 ng/0.1 mL; d). Note the lack of ERK 1/2
immunoreactivity in control animals and its increased expression after IH and leptin
injections. Calibration marks in panel (a) indicates 100 μm and applies to (a-d).
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Figure 3.7. Fluorescent (a-c) photomicrographs showing the effect of IH on Ob-Rb (a)
and ERK 1/2 (b) expression in carotid body glomus cells. Note that Ob-Rb and ERK 1/2
are co-expressed in the same cells (c). Calibration mark in (a) represents 100 μm and
applies to (a-c).
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Figure 3.8. Western blots showing the presence of pSTAT3 (a), STAT3 (b), and SOCS3
(c) in carotid bodies after IH. Note that IH does not alter the level of pSTAT3 (a) or
STAT3 (b), although there was a clear trend towards a decrease expression of the
pSTAT3 protein above that seen in normoxic controls (a). Also note that IH significantly
increases (*) the expression of the SOCS3 protein above that seen in normoxic controls.
p values are indicated. n=5-6.
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3.4 Discussion
These data provide the first direct evidence that the activity of cells within the
carotid body which express both leptin and the Ob-R’s are altered during IH during the
time plasma levels of leptin are elevated by IH. These data can be interpreted to suggest
that leptin, either through an autocrine/paracrine mechanism or from other sources that
contribute to circulatory levels, may alter the function of carotid body cells and possibly
modulate chemosensitivity during hypoxic conditions. This suggestion is supported by
the finding in this study that intravenous injections of leptin not only induced Fra-1
activity within carotid body cells that expressed leptin and the Ob-Rb, but also increased
leptin expression within these cells. Additionally, it was found that IH induced changes in
a number of downstream signalling molecules associated with the JAK2/STAT3
signalling pathway following leptin receptor stimulation. It is known that activation of
Ob-Rb by leptin results in the phosphorylation of STAT3 which leads to an increase in
the expression of the SOCS3 protein. SOCS3 can then act as a negative feedback of the
Ob-Rb signalling mechanism (Bjorbaek et al., 1998a, 1999). In this study, SOCS3 levels
were found to be increased in carotid bodies following IH exposure, further supporting
the suggestion that activation of Ob-Rb occurred as a result of elevated leptin levels.
Finally, it was observed that leptin injections and IH increased the expression of ERK1/2
also suggesting that activation of Ob-Rb may also use an alternate signalling pathway
within these cells to alter transcription. However, the source of the leptin exerting an
effect on the carotid body cells remains unknown.
The finding that leptin is expressed within the carotid body is supported by an
earlier study showing that the glomus cells of the carotid body expressed leptin
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(Porzionato et al., 2011). However, this study has also shown that IH increases the
expression of leptin within these cells, a finding also observed following systemic
injections of leptin. Furthermore, these leptin producing carotid body cells expressed the
immediate early gene product Fra-1 in responses to IH and the intravenous injection of
leptin. Taken together, these findings can be interpreted to suggest that carotid body
glomus cells, when activated by leptin during IH, further increase their production of
leptin so that leptin can either exert an effect on the cell itself or on neighbouring cells to
alter their ability to transduce changes in arterial PO2. The co-expression of Ob-Rb within
these carotid body leptin producing cell types further supports a potential
autocrine/paracrine mechanism of action that is well documented in various tissues
including pituitary, adipose tissue and the gastrointestinal tract (Siegrist-Kaiser et al.,
1997; Fruhbeck et al., 1997; Jin et al., 2000; Bado et al., 1998; Mix et al., 2000; Sobhani
et al., 2000). The finding that carotid body glomus cells express the Ob-Rb is consistent
with previous studies (Messenger et al., 2012; Porzionato et al., 2011). Thus, these
combined observations suggest the possibility that the release of leptin by carotid body
cells during IH may contribute to the elevated plasma leptin levels observed after IH,
although it is unlikely to account for the total rise in the plasma leptin levels, and that
leptin may then exert an effect back onto the carotid body cells.
Interestingly, it was observed that IH induced change in the expression of both the
long form (Ob-Rb) and the short form (Ob-R100) of the leptin receptor within the carotid
body. No other isoforms of Ob-R’s were detected in these studies. As expected with an
elevated plasma level of leptin, the Ob-Rb was found to be down-regulated (Mercer et al.,
1997; Bennett et al., 1998; Uotani et al., 1999; Mitchel et al., 2009). The Ob-Rb is
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generally accepted as the main signalling form of the Ob-R isoforms and a decrease in
the levels of this receptor within glomus cells would then be expected to reduce the
sensitivity of the cells to leptin. The exact mechanism by which the decrease in carotid
body Ob-Rb expression occurs is unknown. However, one possible explanation may be
that the increased exposure to leptin, both local and circulating, stimulates ligand-induced
endocytosis (Bennett et al., 1998; Uotani et al., 1999). In animals lacking circulating
leptin, such as the ob/ob mouse, or lacking Ob-Rb signalling due to mutations in the ObRb gene, such as in the Zucker obese rat, Ob-Rb expression is significantly up-regulated
(Mercer et al., 1997; Bennett et al., 1998) most likely due to lack of Ob-Rb signalling.
Additionally, during fasting, where leptin levels drop, Ob-Rb gene expression is upregulated (Baskin et al., 1998; Bennett et al., 1998). However in the case of increased
leptin exposure, as seen in the IH model used (Messenger et al., 2012), previous studies
have supported a down-regulation of Ob-Rb (Bennett et al., 1998; Uotani et al., 1999).
It was also found in this study that the short form of the leptin receptor (Ob-R100),
which likely represents the Ob-Ra isoform of the receptor, was up-regulated after the IH
stimulus. Although the exact functions of the Ob-Ra isoform are not clear, it is generally
believed that the OB-Ra may function in leptin’s transport across the blood-brain barrier
(Golden et al., 1997; Bjorbaek et al., 1998). In addition, it has been suggested that OB-Ra
may function in leptin’s degradation (Iida et al., 1996; Merabet et al., 1997; Sharma et al.,
1997). Thus increased Ob-Ra levels may aid in mediating leptin transport from the
circulation into the carotid body, as well as the degradation of the over-expressed
cytokine within the carotid body cells after exposure to IH. Finally, it has been
documented that leptin signalling is not exclusively mediated via the long-form receptor
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but may also occur via the MAPK pathway through activation of both OB-Rb and OB-Ra
isoforms (Bjorbaek et al., 1997) both of which are present in glomus cells.
Transcription within cells following leptin activation of the Ob-Rb is not
mediated by only the JAK/STAT signalling pathway (Kloek et al., 2002). Activation of
JAK2 also leads to activation of ERK1/2 (Kloek et al., 2002). The activation of ERK1/2
by leptin has previously been shown in the hypothalamus where it is known to mediate
food intake, body weight and thermogenic sympathetic outflow (Rahmouni et al., 2009).
Although we have shown that leptin activates the JAK2/STAT3 pathway in carotid body
cells, a finding consistent with an earlier study (Messenger et al., 2012), this study has
also shown the potential for an additional signalling pathway within carotid bodies by
identifying a downstream regulator of MAPK signalling, pERK1/2 in animals exposed to
IH. As increased pERK1/2 was also observed in carotid body cells following systemic
leptin injections suggests multiple signalling pathways for leptin signalling in the carotid
body.
It was found that IH did not alter STAT3 or pSTAT3 protein levels within the
carotid body. This suggests that STAT3 activation in the carotid bodies of animals
exposed to IH was the resulted of the activation of the Ob-Rb. The subsequent reduction
in levels of the Ob-Rb after IH was likely due the increased exposure of the receptor to
leptin which is known to induce a down-regulation of Ob-Rb (Uotani et al., 1999;
Bennett et al., 1998). The trend towards decreased levels of pSTAT3 also suggest that
SOCS3 would eventually rise and thus inhibit further phosphorylation of STAT3 by
exerting an effect on JAK2 (Bjorbaek et al., 2000), which then may account for the
relatively small change in pSTAT3 expression observed after IH. It was found in this
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study that SOCS3 was elevated in the IH exposed animals. Thus activation of SOCS3
would essentially shut down Ob-Rb signalling through the activation of JAK2/STAT3
pathway. In ob/ob mice, peripheral administration of leptin induces SOCS3 mRNA
(Bjorbaek et al., 1998a). The same result has been shown in Ay/α mice, a rodent model of
leptin-resistant obesity (Bjorbaek et al., 1998a). In conditions of chronically increased
leptin signalling, such as obesity (Ahima and Flier, 2000; Friedman and Halaas, 1998),
high SOCS3 levels are found within various regions of the nervous system, including the
nodose ganglion and the hypothalamus (Reed et al., 2010; de Lartigue et al., 2011).
In summary, this study has provided evidence for the co-expression of leptin, ObRb and Fra-1 within carotid body cells, and that during IH these proteins are altered, as is
the plasma levels of leptin. Additionally, IH activates a series of down-stream signalling
pathways following the activation of the Ob-Rb. Taken together, these data suggest
leptin produced locally by the glomus cells exerts an excitatory effect in an
autocrine/paracrine fashion on glomus cells and possibly directly on carotid body afferent
nerve fibers which have been also shown to express the Ob-Rb (Messenger et al., 2012).
Leptin has been implicated in respiratory control (Tankersley et al., 1998; O'Donnell et
al., 2000; Inyushkin et al., 2009) and cardiovascular control (Arnold, et al., 2009; Mark et
al., 2009; Ciriello and Moreau, 2012) involving carotid chemoreceptors. In ob/ob mice,
leptin replacement restored their rapid breathing pattern (Tankersley et al., 1998).
Additionally, leptin microinjection into the NTS, the site of primary chemoreflex afferent
termination, results in increased pulmonary ventilation, respiratory volume and electrical
activity to inspiratory muscles (Inyushkin et al., 2009), increases in sympathetic activity
and a potentiation of the chemoreceptor reflex (Ciriello and Moreau, 2012). Thus, these

92

data suggest the possibility that leptin exerts modulatory effects at multiple levels
throughout the chemoreceptor reflex pathway.
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Chapter 4

4

Effect of Chronic Intermittent Hypoxia on Leptin and Leptin
Receptor Protein Expression in the Carotid Body
4.1 Introduction
Obstructive sleep apnea (OSA), characterized by brief, repeated upper airway
collapse during the patients sleep cycle (Dempsey et al., 2010; Gonzalez et al., 2012), is a
pathophysiological disorder observed in both normal weight (Pamidi et al., 2012) and
obese individuals (Lubrano et al., 2012). The repetitive cessation of night time breathing
exposes these individuals to chronic intermittent hypoxia (CIH), a repeated depression of
arterial partial pressure of oxygen (PO2) (Dempsey et al., 2010; Gonzalez et al., 2012).
Furthermore, if left untreated, OSA in these individuals increases the risk of developing
cardiovascular and metabolic disorders (Dempsey et al., 2010; Marin et al., 2005;
Shamsuzzaman et al., 2003). An animal model has been developed to study the effects of
CIH resulting from OSA (Fletcher et al., 1992), in which both arterial pressure and
sympathetic nerve activity have been shown to be increased during exposure to CIH, and
these autonomic effects are dependent on the integrity of the carotid body chemoreceptor
reflex (Fletcher, 2000).
The carotid bodies, located bilaterally at the bifurcation of the carotid arteries,
have been shown to contain oxygen-sensing type-I (glomus) cells (McDonald, 1981). The
glomus cells within the carotid body transduce the PO2 within arterial blood and transmit
this information via the carotid sinus nerve to the central nervous system (Heymans et al.,
1930; Nurse, 2005), which in turn activates multiple homeostatic mechanisms including
those involving the respiratory and cardiovascular systems (Kumar, 2009; Schultz and Li,
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2007). Although the mechanisms by which PO2 in the glomus cells signals carotid body
afferent neurons remain equivocal, a number of signaling molecules have been implicated
including acetylcholine, dopamine, norepinephrine, histamine, adenosine and adenosine
triphosphate (Bock, 1980; Conde and Monteiro, 2004; Eyzaguirre and Zapata, 1968;
Gomez-Nino et al., 1990; McQueen and Ribeiro, 1981; Nurse, 2005; Nurse, 2010;
Shirahata et al., 2007; Spyer et al., 2004).
Recently, leptin and isoforms of its receptor have been identified within carotid
body glomus cells (Messenger and Ciriello, 2013; Messenger et al., 2012; Porzionato et
al., 2011). Additionally, 8 hours of intermittent hypoxia exposure activates glomus cells
that expressed the long form of the leptin receptor (OB-Rb) (Messenger et al., 2012), and
increases the levels of leptin, the short form of the leptin receptor (OB-R100), and
downstream mediators of leptin signaling including, extracellular signal-regulated kinase
1/2 (ERK 1/2) and suppressor of cytokine signaling 3 (SOCS3) proteins, while
decreasing phosphorylated signal transducer and activator of transcription 3 (pSTAT3),
and OB-Rb protein expression within these cells (Messenger and Ciriello, 2013). Leptin,
the 16 kDa hormonal product of the obese gene, produced primarily by adipocytes in
proportion to adiposity (Caro et al., 1996; Lonnquist et al., 1995), normally plays an
important role in metabolism and energy balance (Bjørbaek and Kahn, 2004; O'Donnell
et al., 2000). This weight-reducing class-I cytokine is thought to signal primarily through
the OB-Rb, one of the six isoforms identified for the leptin receptor (OB-Ra-f) (Lee et al.,
1996; Wang et al., 1996). In addition, leptin signaling has been suggested to play an
important role in cardiovascular regulation. Central administration of leptin increases
sympathetic nerve activity, arterial pressure, and heart rate (Dubinion et al., 2011;
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Rahmouni et al., 2003; Shirasaka et al., 2003). Furthermore, central injections of leptin
potentiate the chemoreceptor reflex (Ciriello and Moreau, 2012) while decreasing the
sensitivity of the vagal component of the baroreceptor reflex (Arnold et al., 2009).
Although 8 hours of intermittent hypoxia, as well as systemic administration of
leptin, alters leptin and downstream leptin signaling proteins within the carotid body
(Messenger et al., 2012; Messenger and Ciriello, 2013), the long term effects of CIH on
leptin and its receptors and downstream signaling molecules within the carotid body are
not known. This study was done to determine whether leptin and leptin signaling proteins
in the carotid bodies were altered in response to short term (7 days) or long term (95
days) exposure to CIH by examining whether: 1) CIH alters leptin and OB-R expression;
2) CIH alters the protein expression of signal transducer and activator of transcription 3
(STAT3) and pSTAT3; 3) CIH alters the expression of suppressor of cytokine signaling 3
(SOCS3), which binds to JAK2 and thus inhibits leptin-induced signaling through the
STAT3 mechanism (Bjørbaek et al., 2000; Fruhbeck, 2006); 4) CIH alters the expression
of ERK1/2 and pERK1/2. OB-Rb, through the activation of the JAK2/STAT3 pathway, is
implicated in transducing most of leptin’s signaling effects within the central nervous
system (Elmquist et al., 1997; Huo et al., 2006; Huo et al., 2007).

4.2 Methods
General Animal Procedures: Experiments were done in male Sprague–Dawley rats
(Charles River Canada, St. Constant, Canada) weighing 211-400 g. All animals were
housed under controlled conditions with a 12 h light/dark cycle. Food and water were
available ad libitum. All experimental procedures were done in accordance with the
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guidelines on the use and care of laboratory animals as set by the Canadian Council on
Animal Care and approved by the Animal Care Committee at the University of Western
Ontario.
Induction of CIH: CIH (n=7 for 7 days; n=4 for 95 days) or normoxia (n=5 for 7 days;
n=4 for 95 days) was induced in animals as previously described (Messenger et al., 2012;
Messenger and Ciriello, 2012). In brief, animals (one/tube) were placed into custom
made cylindrical plexiglass tubes with a zero-pressure escape valve (11 cm diameter x 33
cm length) inside an airtight plexiglass chamber. The animal was allowed to freely move
within each tube. The chamber was attached to computer-controlled solenoid valves
responsible for regulating the inflow of either pressurized room air (21% O2) or 100%
medical N2. The solenoid valves were connected to a computerized timer system that
allowed for the control of a total hypoxic (100% medical N2) stimulus delivery of 80 s
followed by a normoxic (21% O2) time of 100 s, for a total continuous repetitive cycle
period of 8 h. Additionally, the controller, attached to detectors for O2 and CO2 within the
chamber, was set at a O2 level of 6.5 % and CO2 level of 0.1% under isobaric conditions
at all times during the delivery of the hypoxic stimulus and recovery phase during which
O2 returned to 20.9%. A control (normoxic) set of animals was simultaneously run in a
similar adjacent chamber through which only room air (21% O2; normoxia) was used for
the gas exchange in isobaric conditions for an 8 h period. Animals were exposed to the 8
h IH stimuli each day of the experimental period during daylight hours.
Carotid Body Protein Extracts and Immunoblot Analysis: Carotid body protein extracts
were obtained following bilateral carotid body excision from the normoxia- or CIHexposed animals as described previously (Messenger and Ciriello, 2012). In brief, the
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carotid bodies (bilaterally) from each animal were snap frozen and pooled and
homogenized in 200µL of RIPA buffer solution (150 mM NaCl, 1 mM NaF, 1 mM
NaVO4, 0.5 mM β-glycerophosphate, 1mM EDTA, 1% Triton-X 100, 50mM Tris-HCL
at pH of 7.5) with a protease inhibitor cocktail (Roche Diagnostics, Laval, Quebec,
Canada). The homogenate was centrifuged at 4°C for 15 min at 2100 RPM. The
supernatant was retained and then centrifuged a second time at 4°C for 20 min at 13200
RPM. The resultant supernatant was retained as the protein preparation. Equal
concentrations of extracted proteins normalized by colorimetric BCA Protein Assay
(Pierce Corp., Madison, Wisconsin, USA) were fractionated in 10% polyacrylamide gel
(Novex, Carlsbad, California, USA) and transferred onto a polyvinylidene fluoride
membrane. Blots were probed using polyclonal rabbit anti-leptin (1:1000, Cat. # sc843;
Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), polyclonal rabbit anti-OBR (1:1000, Cat. # OBR12-A; Alpha Diagnostics International Inc., San Antonio, Texas,
USA), affinity purified anti-OB-Rb (1:1000, Cat. # CH14104; Neuromics, Edina,
Minnesota, USA), polyclonal rabbit anti-SOCS3 (1:1000, Cat. # ab16030; Abcam Inc.,
Cambridge, Massachusetts, USA), monoclonal rabbit anti-STAT3 (1:2000, Cat. # 4904S;
Cell Signaling Technology, Danvers, Massachusetts, USA), polyclonal rabbit antipSTAT3 (1:1000, Cat. #9131S; Cell Signaling Technology, Danvers, Massachusetts,
USA), monoclonal rabbit anti-ERK1/2 (1:1000, Cat. # 4695S; Cell Signaling
Technology, Danvers, Massachusetts, USA), monoclonal rabbit anti-pERK1/2 (1:1000,
Cat. # 4376S; Cell Signaling Technology; Danvers, Massachusetts, USA), and
monoclonal horseradish peroxidase-conjugated β-actin (1:50000, catalog no. A3854,
Sigma-Aldrich, St. Louis, Missouri, USA) diluted in 5% milk-1X Tris-buffered saline-
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Tween 20 buffer and with horseradish peroxidase conjugated donkey anti-rabbit IgG or
donkey anti-chicken IgG (1:10000, catalog # 711- 035-152 or 703-035-155, respectively;
Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA) diluted in 5%
milk-1X

Tris-buffered

saline-Tween

20

buffer

as

the

secondary

antibody.

Immunoreactive bands were visualized using an enhanced chemiluminescence detection
system (Millipore Canada Ltd, Toronto, Ontario, Canada).
Statistical Analysis: Statistical comparisons between Western blots of the normoxia and
CIH exposed animals at each time point, and those between 7 and the 95 day time point
were made using a two-tailed, unpaired Student t-test. In all comparisons, a minimum pvalue of < 0.05 was taken to indicate statistical significance (GraphPad Prism; GraphPad
Software, San Diego, California, USA).

4.3 Results
Effects of 7 and 95 day CIH on Leptin, OB-Rb and OB-R100 Protein Expression within
the Carotid Body: Figure 4.1a shows that the protein expression of leptin within the
carotid body of animals exposed to CIH for 7 days was significantly (p = 0.040) lower by
approximately 20%, compared to normoxic controls. Additionally, the protein expression
of OB-Rb was significantly (p = 0.042) increased by about 92% (Fig. 4.2a), whereas that
for OB-R100 was not changed (Fig. 4.3a) compared to normoxic controls. After 95 day
exposure to CIH, carotid body leptin protein levels were significantly (p = 0.027) lower
by about 45% compared to normoxic controls (Fig. 4.1b). Furthermore, the expression of
OB-Rb was significantly (p=0.040) increased by about 124% (Fig. 4.2b), whereas that
for OB-R100 was not changed (Fig. 4.3b) compared to normoxic controls at the 95 day
period.
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Figure 4.1. Western blots showing protein expression of leptin in carotid bodies after 7
day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH significantly
(*) decreases the level of leptin below that seen in normoxic controls at both time points.
p values are indicated. n=4-7.
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Figure 4.2. Western blots showing protein expression of OB-Rb in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH
significantly (*) increases the level of OB-Rb protein above that seen in normoxic
controls at both time points. p values are indicated. n=4-7.
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Figure 4.3. Western blots showing protein expression of OB-R100 in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH does
not significantly alter the expression of the Ob-R100 protein above that seen in normoxic
controls. p values are indicated. n=4-7.
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Figure 4.4. Western blots showing protein expression of STAT3 in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH does
not alter the expression of the STAT3 protein above that seen in normoxic controls at 7
days, but significantly increases it at 95 days compared to normoxic controls . p values
are indicated. n=4-7.
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Effects of 7 and 95 day CIH on STAT3, pSTAT3, SOCS3, ERK1/2, and pERK 1/2
Protein Expression within the Carotid Body: As shown in Figure 4.4, exposure of the
animal to 7 (Fig. 4.4a) days of CIH did not significantly alter STAT3 protein levels
within the carotid body. However, after 95 days of CIH exposure, STAT3 protein levels
were significantly (p = 0.050) higher (~ 40%) compared to normoxic controls (Fig. 4.4b).
On the other hand, only within the 7 day group was there a significant (p = 0.024)
decrease by about 66% in pSTAT3 (Fig. 4.5a) compared to normoxic animals, while
there were no changes in pSTAT3 observed within the 95 day group between normoxic
and CIH groups (Fig. 4.5b).
Protein expression levels of SOCS3 were significantly (p = 0.034) higher by
111% in the 7 day group compared to normoxic controls (Fig. 4.6a). On the other hand,
there were no changes in SOCS3 protein after exposure to 95 days of CIH compared to
normoxic animals (Fig. 4.6b).
Figure 7 summarizes the effects of CIH on ERK 1/2 protein expression within the
carotid body. After 7 days of CIH exposure, ERK 1/2 protein levels were decreased
(p=0.033; by about 43% of normoxic controls) (Fig. 4.7a), whereas at the 95 day period,
the protein levels of ERK 1/2 were significantly increased (p=0.010) by about 114%
compared to normoxic controls (Fig. 4.7b). pERK 1/2 levels followed a similar pattern to
that observed for ERK 1/2, but were only significant (p=0.008) at the 95 day period (Fig.
4.8b) where protein levels of pERK 1/2 increased by about 252%.
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Figure 4.5. Western blots showing protein expression of pSTAT3 in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH
decreases the expression of the STAT3 protein below that seen in normoxic controls at 7
days, but does not alter it after 95 days compared to normoxic controls. p values are
indicated. n=4-7.
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Figure 4.6. Western blots showing protein expression of SOCS3 in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH
increases the expression of the SOCS3 protein above that seen in normoxic controls at 7
days, but does not alter it after 95 days compared to normoxic controls. p values are
indicated. n=4-7.
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Figure 4.7. Western blots showing protein expression of ERK1/2 in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH
decreases the expression of the ERK1/2 protein below that seen in normoxic controls at 7
days, while increasing it above that seen in normoxic controls at 95 days. p values are
indicated. n=4-7.
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Figure 4.8. Western blots showing protein expression of pERK1/2 in the carotid bodies
after 7 day (a) and 95 (b) days of exposure to normoxia or CIH (IH). Note that CIH does
not alter pERK1/2 after 7 days compared to normoxic controls, but increases the
expression of the pERK1/2 protein above that seen in normoxic controls at 95 days. p
values are indicated. n=4-7.
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Effects of Normoxic and CIH Exposure Time on Carotid Body Leptin, OB-Rb, OBR100, pSTAT3/STAT3 ratio, STAT3, ERK1/2, pERK 1/2 and SOCS3 Protein Levels:
Table 1 summarizes comparisons between the effects of normoxia or CIH on protein
expression within the carotid body between the 7 and 95 day exposure groups. Leptin
protein levels were found to be significantly decreased in both the normoxic controls and
the CIH group at the 95 day period compared to the 7 day period. On the other hand, no
changes were found between the two time periods in either the normoxic or CIH group
for OB-Rb or OB-R100. Similarly, no changes were observed in either STAT3 or pSTAT3
protein levels in the normoxic group between the two different time points. However, in
the CIH group, STAT3 levels were lower by about 51% in the 95 day group compared to
the 7 day group, while pSTAT3 levels were increased by about 58% in the 95 day group
compared to the 7 day group. SOCS3 levels were not different between to the two points
in the normoxic animals, but in animals exposed to CIH SOCS3 levels were significantly
reduced by about 66% in the 95 day group compared to the 7 day group. Finally, only in
the normoxic controls were the levels of ERK 1/2 reduced (by about 73%) at the 95 day
time period compared to the 7 day time period.
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Table 1.
Effects of normoxia and CIH exposure time on the protein expression within the carotid
body of leptin, OB-Rb, OB-R100, pSTAT3/STAT3 ratio, STAT3, ERK1/2, pERK 1/2 and
SOCS3 protein levels.
________________________________________________________________________
Stimulus

Normoxia

CIH

________________________________________________________________________
p value

p value

________________________________________________________________________
Protein
Leptin

↓ 0.0006*

↓ 0.050*

OB-Rb

0.496

0.163

OB-R100

0.355

0.111

STAT3

0.385

↓ 0.016*

pSTAT3

0.289

↑ 0.0004*

SOCS3

0.442

↓ 0.050*

ERK1/2

↓ 0.004*

0.455

pERK1/2

0.242

0.266

p values are from statistical comparisons between 7 day and 95 day (↑, increase; ↓ ,
decrease) exposure times for the normoxic control group or the CIH group. n=4-7. *,
statistical significance.
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4.4 Discussion
This study has provided evidence indicating that CIH exerts an effect on leptin
and leptin receptors, and on downstream signaling proteins associated with leptin
receptor activation within the carotid body. This is based on the finding that carotid body
cells not only express leptin and the leptin receptors OB-Rb and OB-R100, but also that
these receptors and leptin protein levels were altered after exposing them to short term (7
days) and long term (95 days) CIH. Additionally, changes were induced by CIH in a
number of downstream signaling molecules associated with the leptin JAK2/STAT3
signaling pathway following activation of the OB-Rb (Fruhbeck, 2006). It is well
documented that OB-Rb activation by leptin results in the phosphorylation and activation
of STAT3 and ERK 1/2. pSTAT3 leads to an increase in the expression of the SOCS3
protein, which can then act as a negative feedback regulator of the OB-Rb signaling
mechanism (Bjørbaek et al., 1999; Bjørbaek et al., 1998a; Fruhbeck, 2006).The increased
phosphorylation of ERK 1/2 suggests that activation of OB-Rb may also use an alternate
signaling pathway within these cells to alter cellular responses in addition to pSTAT3
(Fruhbeck, 2006). Taken together, these data can be interpreted to suggest that leptin,
either through an autocrine/paracrine mechanism or from other sources that contribute to
circulatory levels, may alter the function of carotid body cells and possibly modulate
chemosensitivity during CIH conditions.
This study has shown that leptin is expressed within the carotid body and that it is
decreased after exposure to CIH for either 7 days or 95 days compared to normoxic
controls. This finding is supported by an earlier study showing that the glomus cells of
the carotid body not only expressed leptin (Messenger and Ciriello, 2013; Porzionato et
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al., 2011), but also that the carotid bodies contain mRNA for leptin (Porzionato et al.,
2011), suggesting that leptin is likely produced within these cells. The decreased leptin
protein expression observed after CIH is in contrast to the increase observed within the
carotid bodies following an acute exposure of 8 hours of intermittent hypoxia exposure
(Messenger and Ciriello, 2013). The increase observed following 8 hours of intermittent
hypoxia was suggested to be due to the increased production of leptin with the glomus
cells or transport of leptin from plasma into these carotid body cells (Messenger and
Ciriello, 2013), as plasma levels of leptin were elevated (Messenger and Ciriello, 2013;
Messenger et al., 2012) and as corresponding changes in the expression of the OB-R100
(likely OB-Ra) were observed in that study (Messenger and Ciriello, 2013). OB-Ra is
thought to function as a carrier protein for leptin’s transport across cell membranes
(Bjørbaek et al., 1998b; Golden et al., 1997). The decreases observed in leptin after CIH
may suggest that a number of different factors may account for these changes, including
alterations in production, uptake, secretion and degradation of the protein within the
carotid body. Although these data could also be interpreted to suggest that carotid body
leptin is no longer involved in leptin signaling within glomus cells, this may not be the
case as plasma levels of leptin remain elevated at both 7 and 95 days after CIH (Moreau
and Ciriello, 2013, unpublished observations), and there is an up-regulation of the
expression of the OB-Rb protein within the carotid body at these time points.
As the promoter of the gene encoding the leptin protein has been shown to be
activated by hypoxia-inducible factor 1-alpha in humans (Grosfeld et al., 2002), and CIH
has been found to increase hypoxia-inducible factor 1-alpha (Peng et al., 2006), a
possible explanation for the decrease in leptin during long term exposure to CIH may be
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that there is a change in secretion of leptin by the glomus cells. This in turn may function
to modulate glomus cell activity or to signal the carotid body afferent fibers. Consistent
with this suggestion, a previous study has identified OB-Rb-like immunoreactivity on
fibers within the carotid sinus nerve and on those within the carotid body (Messenger et
al., 2012). This study also demonstrated intermittent hypoxia and systemic leptin
injection induces pSTAT3 in these fibers coursing through the carotid body. In addition,
acute intermittent hypoxia and systemic injections of leptin have been shown to increase
Fra 1/2 protein expression within both glomus cells and petrosal ganglion neurons,
suggesting a change in the cellular activity of the carotid chemoreflex (Messenger et al.,
2012). Furthermore, the co-expression of OB-Rb within these carotid body leptin
producing glomus cells (Messenger et al., 2012) supports the suggestion of a potential
autocrine/paracrine mechanism, similar to that demonstrated in other tissues (Bado et al.,
1998; Fruhbeck et al., 1997; Jin et al., 2000; Mix et al., 2000; Siegrist-Kaiser et al., 1997;
Sobhani et al., 2000). However, changes in secretion of leptin from the carotid body is
unlikely to account for the decreased leptin levels within the carotid body as the protein
expression levels of the OB-R100 were not changed.
Exposure to CIH resulted in changes to OB-Rb, but not OB-R100. Following both
7 days and 95 days of CIH, OB-Rb protein expression levels were increased whereas
those for OB-R100 were unchanged compared to normoxic controls. OB-R100 denotes a
100 kDa band potentially representing OB-Ra, OB-Re or both. OB-Ra is a well-known
transport receptor, playing a role in leptin passage into and out of cells (Bjørbaek et al.,
1998b, Golden et al., 1997). Additionally, the OB-Ra may play a role in leptin
degradation (Merabet et al., 1997; Sharma et al., 1997). The OB-Re is considered a
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soluble receptor which binds leptin in the circulation and is involved in maintenance of
circulating leptin levels by binding or releasing leptin within the blood for physiological
functions (Huang et al., 2001; Li et al., 1998).
The change observed in OB-Rb, the primary receptor transducing leptin’s
physiological effects (Fruhbeck, 2006), suggests a possible change in sensitivity or
signaling strength. It is well-known that leptin and its receptor may undergo ligandinduced endocytosis as well as increase receptor expression in situations of low ligand
availability (Bennett et al., 1998; Mercer et al., 1997; Mitchell et al., 2009; Uotani et al.,
1999). Thus, as observed in this study, the decreased local leptin levels may account for
an increase in OB-Rb expression. However, if it is accepted that leptin levels have
decreased within the glomus cells in response to increased release, the increased OB-Rb
expression may suggest a mechanism by which leptin plays a role in the facilitation of the
carotid chemoreceptor reflex (Ciriello and Moreau, 2012).
To investigate whether leptin receptor activity was altered during CIH the ratio of
pSTAT3:STAT3 protein was examined in the carotid body. Decreased pSTAT3:STAT3
was observed following 7 days of CIH suggesting OB-Rb activation was decreased. As it
is well-known that SOCS3 represents a negative feedback on the STAT3 signaling
cascade (Bjørbaek et al., 1999; Bjørbaek et al., 2000; Fruhbeck, 2006), it was not
unexpected to find that CIH concomitantly increased SOCS3 protein levels within the
carotid body. This increase in SOCS3 would be expected to eventually reduce STAT3
phosphorylation (Bjørbaek et al., 1999; Bjørbaek et al., 2000; Fruhbeck, 2006), although
the time course for this to occur, as well as the strength of inhibition of this system in the
carotid body, is not known. Interestingly, no changes in pSTAT3 or SOCS3 were
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observed after 95 day exposure to CIH compared to the normoxic groups; however, when
compared to animals exposed to 7 days of CIH, pSTAT3 was elevated while SOCS3 was
decreased after 95 days of CIH exposure. These findings can be interpreted to suggest
that an increased sensitivity may have occurred to any incoming signal that there is an
elevated sensitization of the system to incoming signals mediated by the JAK2/STAT3
pathway (Howard et al., 2004; Kievit et al., 2006; Mori et al., 2004). This would be the
result of reduced SOCS3, which would be expected to increase the phosphorylation of
STAT3 by JAK2, and thus allow the transduction of the incoming signal (Bjørbaek et al.,
1999; Bjørbaek et al., 2000). In normoxic controls no changes in pSTAT3 or SOCS3
were observed between the animals exposed for 7 and 95 days.
Transcription within cells after leptin activation of the OB-Rb may also be
mediated through the JAK2 pathway activating ERK1/2 (Fruhbeck, 2006; Kloek et al.,
2002). Consistent with this suggestion, carotid body exposure to CIH for 95 days resulted
in an increase in pERK1/2 protein expression. The functional significance of these
findings is not clear. However, the observation of a downstream regulator of MAPK
signaling within carotid bodies suggests an additional signaling pathway by which leptin
may exert an effect on glomus cell chemoreceptor transduction. ERK 1/2 has also been
implicated in the developmental regulation of the carotid body as ERK 1/2 protein levels
have been shown to be lower in human fetuses compared to infants or young adults
(Porzionato et al., 2010). Interestingly, in these studies ERK 1/2 protein levels within the
carotid body were found to be decreased between 7 and 95 day normoxia exposure
groups suggesting that these changes may be related to aging. However, the lack of
change of ERK 1/2 between the two CIH groups could be interpreted that ERK1/2 was
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activated as a result of CIH, consistent with previous observations (Messenger and
Ciriello, 2013).
The data obtained in this study have provided evidence for a potential leptin
signaling pathway within the carotid body, which is activated during CIH. These findings
taken together with the finding that local leptin levels are altered after CIH suggest that
leptin may exert an effect through an autocrine/paracrine mechanism to either activate
neighboring glomus cells or carotid body afferent fibers that co-express OB-Rb
(Messenger et al., 2012; Messenger and Ciriello, 2013). Although the functional role of
the activation of JAK2/STAT3 pathway within the carotid body has not yet been
delineated, it appears to be activated in response to elevations in circulating leptin levels
(Messenger and Ciriello, 2013), which also occur following exposure to intermittent
hypoxia (Messenger et al., 2012; Messenger and Ciriello, 2013).
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Chapter 5

5

Angiotensin Converting Enzyme Inhibition Affects Leptin and
Downstream Indicators of Leptin Signaling in the Carotid
Body
5.1 Introduction
The carotid body is a highly vascularized organ located bilaterally at the
bifurcations of the common carotid arteries (Heymans et al., 1930; Nurse, 2005). The
carotid body, composed of specialized oxygen-sensing type-I glomus cells, signals
carotid sinus nerve endings that transmit the afferent information to the nucleus of the
solitary tract (Ciriello et al., 1994), activating homeostatic mechanisms involving
respiratory, cardiovascular and hormonal systems (Schultz and Li, 2007; Kumar, 2009).
There are now considerable data suggesting that substances within the circulation
gain access to carotid body glomus cells and alter their excitability (Allen 1998; Chen et
al., 2005; Leung et al., 2000, 2003; Nurse & Piskuric, 2012; Peng et al., 2006). One
vasoactive compound that has been shown to alter the discharge of carotid body afferent
fibers independent of its circulatory effects is angiotensin II (ANG II) (Allen 1998;
Leung et al., 2000). The carotid body has been shown not only to contain ANG II binding
sites (Allen, 1998), but to also possess its own intrinsic renin-angiotensin system (RAS)
(Lam & Leung, 2002), suggesting that ANG II within the carotid bodies may act in an
autocrine or paracrine manner. Key elements of the RAS, including protein and mRNA
of angiotensinogen as well as mRNA of angiotensin I converting enzyme (ACE) have
been localized to the type-I glomus cells (Lam & Leung, 2002). A role for ANG II in
chemosensitivity is supported by the finding that gene expression for the ANG II type 1
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receptor (AT1R) is up-regulated in the carotid bodies during chronic hypoxia (Leung et
al., 2000; Fung et al., 2002), and this increased expression of the AT1R is associated with
the increased sensitivity of carotid chemoreceptors (Leung et al., 2000; Fung et al., 2001,
2002). In addition, administration of the ANG II type 1 receptor (AT1R) antagonist
losartan abolishes these effects on chemoreceptors (Allen, 1998; Leung et al., 2000),
including the increased intracellular calcium levels in type-I cells induced by ANG II
(Fung et al., 2001). Consistent with these results, a recent study has demonstrated that
signaling through the AT1R is critical for carotid chemoreceptor sensitivity and signal
transduction of the carotid chemoreceptor reflex during hypoxia (Marcus et al., 2010).
The increases in intracellular calcium induced by ANG II suggest that through
activation of the AT1R, ANG II may impact vesicle secretion from type-I glomus cells
and therefore promote the release of other potential modulators involved in
chemoreceptor function and for the signal transduction of glomus cells to the carotid
sinus nerve (Gomez-nino et al., 1990; Eyzaguirre and Zapata, 1968; Bock, 1980). One
possibility may be that ANG II may signal changes in leptin signaling within the carotid
body as ANG II signaling is known to affect leptin production and secretion other tissues
such as ventricular myocytes, bone marrow and adipocytes (Cassis et al., 2004; Danser et
al., 1999; Haznedaroglu and Buyukasik, 1997; Haznedaroglu et al., 1996; Rajapurohitam
et al., 2006, 2012). Leptin is a 16 kDa protein product of the obese gene and is produced
in proportion to, and secreted primarily but not exclusively, by adipocytes (Lonnquist et
al., 1995; Caro et al., 1996). Circulating leptin may be an indicator of body fat content
and acts as a satiety hormone as well as increasing energy expenditure to balance body
energy stores (Lonnquist et al., 1995; Caro et al., 1996). Leptin signals primarily through
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the long-form leptin receptor (OB-Rb) although 6 splice variants of the OB-R exist (OBRa-OB-Rf) of which only a few have known functions (Lee et al., 1996; Wang et al.,
1996). Leptin has been shown to possess a signaling capability within the carotid body
(Messenger et al., 2012; Messenger and Ciriello, 2103), and both circulating and carotid
body protein expression of leptin have been found to increase in response to intermittent
hypoxia (IH) challenge (Messenger et al., 2012; Messenger and Ciriello, 2013), although
its function within carotid body glomus cells remains unclear. The discovery of leptin as
well as 4 of leptin’s receptor isoforms within carotid body glomus cells (Messenger et al.,
2012, 2013; Porzionato et al., 2011), as well as the finding that increased circulating
leptin levels induce phosphorylated signal transducer and activator of transcription 3
(pSTAT3) and immediate early gene Fra-1 expression within glomus cells (Messenger et
al., 2012) is suggestive that the adipokine may play a role in chemosensitivity.
ANG II has been shown to be released and is required along with increased
sympathetic nerve activity for the chronic hypertension in both human and the animal
model of obstructive sleep apnea (OSA) (Fletcher et al., 1999, 1992a/b; Moller et al.,
2003; Yuan et al., 2004). In addition, in the animal model of OSA, circulating and carotid
body leptin is elevated (Messenger et al., 2012; Messenger and Ciriello, 2013), a finding
consistent with clinical data (Phillips et al., 2000; Harsch et al., 2003). However, it is not
known whether ANG II may affect leptin signaling in the carotid body which in turn may
contribute to altered sensitivity within the chemoreceptor reflex pathway (Ciriello and
Moreau, 2012, 2103). Therefore, this study was done to determine: (1) whether, selective
chronic inhibition of ACE has an effect on circulating levels of leptin during IH; (2)
whether glomus cells expressing the AT1R co-express leptin and the OB-Rb, and whether
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AT1R levels in carotid bodies are altered following exposure to IH; (3) whether chronic
inhibition of ACE alters leptin, OB-R or downstream mediators of long-form leptin
receptor signaling within the carotid body.

5.2 Methods
General Animal Procedures: Experiments were done in male Sprague–Dawley rats
(Charles River Canada, St. Constant, Canada) weighing 250-350 g. All animals were
housed under controlled conditions with a 12 h light/dark cycle. Food and water were
available ad libitum. All experimental procedures were done in accordance with the
guidelines on the use and care of laboratory animals as set by the Canadian Council on
Animal Care and approved by the Animal Care Committee at the University of Western
Ontario.
Angiotensin Converting Enzyme Inhibition: Inhibition of angiotensin converting
enzyme was performed by administration of captopril (Sigma-Aldrich, St. Louis,
Missouri, USA) in the drinking water (2 mg/ml) of each animal three days prior to IH
(n=7) or normoxic conditions (n=7). Captopril was freshly dissolved daily in the drinking
water which was monitored daily. It was calculated that the animals received 146 ± 6
mg/kg/day. At this dose, ACE inhibition has been shown to occur (Schiffrin & Genest,
1982; Ferrone & Antonaccio, 1979).
Induction of IH: IH or normoxia (8 h) was induced in the captopril or losartan treated
animals and in a separate set of animals that were not treated with the drugs (IH, n=8;
normoxia, n=8) as previously described (Messenger et al., 2012; Messenger and Ciriello,
2013). In brief, animals (one/tube) were placed into custom made cylindrical plexiglass
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tubes with a zero-pressure escape valve (11 cm diameter x 33 cm length) inside an
airtight plexiglass chamber. The animal was allowed to freely move within each tube.
The chamber was attached to computer-controlled solenoid valves responsible for
regulating the inflow of either pressurized room air (21% O2) or 100% medical N2. The
solenoid valves were connected to a computerized timer system that allowed for the
control of a total hypoxic (100% medical N2) stimulus delivery of 80 s followed by a
normoxic (21% O2) time of 100 s, for a total continuous repetitive cycle period of 8 h.
Additionally, the controller, attached to detectors for O2 and CO2 within the chamber,
was set at a O2 level of 6.5 % and CO2 level of 0.1% under isobaric conditions at all
times during the delivery of the hypoxic stimulus and recovery phase during which O2
returned to 20.9%. A control (normoxic) set of animals was run simultaneously in a
similar adjacent chamber through which only room air (21% O2; normoxia) was used for
the gas exchange in isobaric conditions for an 8 h period. Animals were exposed to the 8h
IH stimuli during daylight hours.

Plasma Collection and Immunoassays: Measurement of plasma levels of leptin and
ANG II were made immediately after the exposure of the animals to IH or the normoxic
stimuli (Messenger et al., 2012; Messenger & Ciriello 2013). Blood samples were
collected by cardiac puncture in 7% ethylenediaminetetraacetic acid at a volume of 10
µl/ml blood. The blood was immediately centrifuged at 10 000 RPM for 10 min at 4 °C
to isolate the plasma which

was removed and stored at -80 °C until analyzed for

hormone content. Plasma samples were analyzed using enzyme immunoassays for rat
leptin (inter-assay variability: 6.5% intra-assay variability: 7.1%; Enzo Life Sciences;
Farmingdale, NY), and rat ANG II (inter-assay variability: <15%; intra-assay variability:
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<10%; Phoenix

Pharmaceuticals,

Burlingame, California, USA) according to

manufacturer instructions. Enzyme immunoassay plates were read on a SpectraMax M5
plate reader using SoftMax Pro v.5 microplate analysis software (Molecular Devices;
Sunnyvale, California, USA).
Carotid Body Protein Extracts and Immunoblot Analysis: Carotid body protein extracts
were obtained following bilateral carotid body excision from the normoxia- or CIHexposed animals as described previously (Messenger et al., 2012; Messenger & Ciriello
2013). In brief, the carotid bodies (bilaterally) from each animal were snap frozen and
pooled and homogenized in 200µL of RIPA buffer solution (150 mM NaCl, 1 mM NaF,
1 mM NaVO4, 0.5 mM β-glycerophosphate, 1mM EDTA, 1% Triton-X 100, 50mM TrisHCL at pH of 7.5) with a protease inhibitor cocktail (Roche Diagnostics, Laval, Quebec,
Canada). The homogenate was centrifuged at 4°C for 15 min at 2100 RPM. The
supernatant was retained and then centrifuged a second time at 4°C for 20 min at 13200
RPM. The resultant supernatant was retained as the protein preparation. Equal
concentrations of extracted proteins normalized by colorimetric BCA Protein Assay
(Pierce Corp., Madison, Wisconsin, USA) were fractionated in 10% polyacrylamide gel
(Novex, Carlsbad, California, USA) and transferred onto a polyvinylidene fluoride
membrane. Blots were probed using: polyclonal rabbit anti-AT1R (Cat. # sc-1173; Santa
Cruz Biotechnology Inc., Santa Cruz, California, USA), polyclonal rabbit anti-leptin
(1:1000, Cat. # sc843; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA),
polyclonal rabbit anti-OB-R (1:1000, Cat. # OBR12-A; Alpha Diagnostics International
Inc., San Antonio, Texas, USA), affinity purified anti-OB-Rb (1:1000, Cat. # CH14104;
Neuromics, Edina, Minnesota, USA), polyclonal rabbit anti-SOCS3 (1:1000, Cat. #
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ab16030; Abcam Inc., Cambridge, Massachusetts, USA), monoclonal rabbit anti-STAT3
(1:2000, Cat. # 4904S; Cell Signaling Technology, Danvers, Massachusetts, USA),
polyclonal rabbit anti-pSTAT3 (1:1000, Cat. #9131S; Cell Signaling Technology,
Danvers, Massachusetts, USA), monoclonal rabbit anti-ERK1/2 (1:1000, Cat. # 4695S;
Cell Signaling Technology; Danvers, Massachusetts, USA), monoclonal rabbit antipERK1/2 (1:1000, Cat. # 4376S; Cell Signaling Technology; Danvers, Massachusetts,
USA), and monoclonal horseradish peroxidase-conjugated β-actin (1:50000, catalog no.
A3854, Sigma-Aldrich, St. Louis, Missouri, USA) diluted in 5% milk-1X Tris-buffered
saline-Tween 20 buffer and with horseradish peroxidase conjugated donkey anti-rabbit
IgG or donkey anti-chicken IgG (1:10000, catalog # 711- 035-152 or 703-035-155,
respectively; Jackson ImmunoResearch Laboratories, West Grove, Pennsylvania, USA)
diluted in 5% milk-1X Tris-buffered saline-Tween 20 buffer as the secondary antibody.
Immunoreactive bands were visualized using an enhanced chemiluminescence detection
system (Millipore Canada Ltd, Toronto, Ontario, Canada).

Immunofluorescence: Immediately after the application of the 8h IH or normoxic stimuli
the animals were anesthetized with 0.3 mL/100g equithesin and perfused transcardially
using 500 mL ice-cold phosphate buffered saline (PBS; 0.01M, pH 7.4) followed by 4%
paraformaldehyde in 0.1 M PBS (Messenger et al., 2012; Messenger & Ciriello 2013).
The carotid arteries at their bifurcations, along with the attached carotid bodies were
removed bilaterally, and stored overnight in Zamboni’s fixative at 4 ºC. The following
day the tissues were gradually dehydrated through a series of alcohols, and placed in
xylene followed by paraffin wax. Serial transverse sections were cut at 6 µm on a RM
2155 microtome (Leica Microsystems Inc., Buffalo Grove, Illinois, USA.), floated in a
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warm water bath and mounted on double-gelatinized glass microscope slides and placed
on a slide warmer. Tissue sections were later de-paraffinized in xylene and rehydrated
using graded alcohol solutions. For each animal, 1 in every 5 slides was stained with
thionin to identify the region of the carotid body and blood vessels. Additionally,
adjacent sections to those stained for thionin from the normoxic and IH-exposed animals
were rinsed in PBS and processed for double-immunofluorescence for Ob-Rb and leptin.
Sections underwent an antigen-retrieval protocol using a citrate buffer (10 mM sodium
citrate/0.05% Tween; pH 6.0) heated to 90-95ºC in a microwave for 15 min and then
were rinsed in PBS before being placed in 5% normal goat serum (Vectastain Elite ABC
Kit, Cat. # PK6100; Vector Laboratories, Burlingame, California, USA) in PBS
containing 0.3% Triton X-100 for 30 min (Messenger et al., 2012). The sections were
later rinsed in PBS and placed overnight (12 h) into a primary polyclonal rabbit antileptin (Cat. # sc843; Santa Cruz Biotechnology Inc.; Santa Cruz, California, USA; 1:1000
in PBS/0.3% Triton X-100) or affinity purified anti-OB-Rb (1:1000, Cat. # CH14104;
Neuromics, Edina, Minnesota, USA) at room temperature. Sections were then rinsed in
PBS and incubated in goat biotinylated anti-rabbit IgG (Vectastain Elite ABC Kit,
Burlingame, California, USA) diluted 1:500 in PBS/ 0.3% Triton X-100 for 1 h.
Following PBS rinses, sections were placed in Streptavidin Alexafluor-488 (Cat. #
S11223; Invitrogen, Burlington, Ontario, USA) diluted 1:100 for 1 h. Following PBS
rinses, sections were exposed to an avidin containing solution for 15 min followed by a
biotin containing solution for an additional 15 min (Avidin/Biotin blocking kit, Cat. # SP2001; Vector Laboratories, Burlingame, California, USA) to block non-specific binding
sites. Sections were then rinsed in PBS and incubated overnight at room temperature in
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primary polyclonal rabbit anti-AT1R (Cat. # sc-1173; Santa Cruz Biotechnology Inc.,
Santa Cruz, California, USA) diluted 1:1000 in PBS/0.3% Triton-X 100 and 5% normal
goat serum. Following PBS washes, the sections were placed in goat biotinylated antirabbit IgG (Vectastain Elite ABC Kit, Burlingame, California, USA) diluted 1:500 in
PBS/ 0.3% Triton X-100 or goat biotinylated anti-chicken IgY (Vectastain Elite ABC
Kit, Burlingame, California, USA) diluted 1:200 in PBS/ 0.3% Triton X-100 for 1 h.
Sections were rinsed in PBS and placed in Streptavidin Texas Red (Code: RPN1233; GE
Healthcare, Baie d’Urfe, QC, Canada) diluted 1:100 for 1 h. Following PBS rinses,
sections were placed in 100% ethanol containing 5% glacial acetic acid on dry ice for 10
min. Sections were then immediately cover-glassed using Fluoromount mountant.

Statistical Analysis: Statistical comparisons between normoxia and CIH exposed animals
were made using a one-tailed, unpaired Student t-test. Statistical comparisons between
plasma values of ANGII or leptin were made using two-way ANOVA followed by
Bonferroni’s post-hoc analysis. In all comparisons, a minimum p-value of < 0.05 was
taken to indicate statistical significance (GraphPad Prism; GraphPad Software, San
Diego, California, USA).

5.3 Results
Plasma ANG II and Leptin Levels Following Captopril Treatment: As previously
reported (Messenger et al., 2012), IH was found to significantly increase plasma ANG II
(p < 0.01) (Fig. 5.1a) about 3 fold above those found in the normoxic control animals and
plasma leptin (Fig. 5.1b) levels approximately 5.9 fold (p < 0.01) above those found in
the normoxic control animals. Following captopril treatment, no differences were found
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between IH and normoxic controls. In addition, in animals treated with captopril, the
increase in leptin following IH exposure was not only abolished, but basal circulating
levels of leptin were found to be significantly (p<0.05) lower than then those observed in
non-captopril treated normoxic controls (Fig. 5.1b).
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Figure 5.1. Bar charts showing the effect of IH on plasma levels of ANG II (a), and
leptin (b) compared to levels observed in normoxic controls under sham (non-captopril
treatment) and captopril treatment. Note that plasma ANG II (a) and leptin (b) are
elevated following IH in the non-captopril treated (sham) group compared to normoxic
group. Additionally, note that captopril treatment not only eliminated the rise in both
ANG II and Leptin following IH, but also lowered the plasma levels of leptin below
control sham levels (b). Values are shown as means ± S.E. *p < 0.01. n=7.
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Leptin, OB-Rb and AT1R Co-expression in Carotid Body: Figure 5.2 shows the effect
of IH on leptin, OB-Rb and AT1R expression within glomus cells of the carotid body.
These cells within the carotid body expressed little leptin (Fig. 5.2a), but some AT1R
(Fig. 5.2b) immunofluorescence under normoxic conditions. However, following
exposure to IH, carotid body glomus cells exhibited an increased expression of leptin
(Fig. 5.2c), OB-Rb (Fig. 5.3e), and AT1R (Fig. 5.2d and 5.2f). As can be seen in Figure
5.2, both leptin and Ob-Rb are expressed within the same carotid body glomus cells that
express the AT1R.
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Figure 5.2. Fluorescent photomicrographs of the carotid body showing glomus cells
immunoreactive to leptin (a,c), Ob-Rb (e) and angiotensin type-1 receptor (AT1R; b,d,f)
following exposure to IH (c,d,e,f) or normoxia (a,b). Note that cells immunoreactive to
leptin and Ob-Rb also contain immunoreactivity to AT1R. Calibration marks indicate 25
µm.
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Effect of IH on AT1R and AT2R in Carotid Body: Figure 5.3 shows the effect of IH on
AT1R and AT2R protein expression in the carotid body. When exposed to IH, the
expression of AT1R was significantly increased by about 33% (Fig. 5.3a). However, the
protein expression of AT2R was not different following IH exposure (Fig. 5.3b).

Effects of Captopril on Leptin within Carotid Body: Figure 5.4 show the effect of
captopril (Fig. 5.4a-c) treatment on carotid body leptin protein levels following IH
exposure. In normoxic animals (Figs. 5.4a), captopril treatment lowered leptin levels to
about 49% of non-treated animals however this effect was not statistically significant. In
the IH animals, captopril (Fig. 5.4b) lowered leptin levels within the carotid body to
about 58%, of levels found within the IH non-treated animals. In addition, when the
effects of captopril (Fig. 5.4c) in the normoxic animals were compared to those in of the
IH animals, it was found that captopril lowered the leptin levels of the IH animals to
about 60% of the normoxic captopril animals (Fig. 5.4c) however this effect was not
statistically significant.
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Figure 5.3. Western blots showing the effect of IH on AT1R (a) and AT2R (b) the protein
expression in the carotid bodies. Note that AT1R protein levels are significantly elevated
following IH, whereas levels of the AT2R are not altered in the carotid bodies. *,
significantly different from normoxic control animals. n=7.
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Figure 5.4. Western blots showing changes in leptin protein within the carotid body
following IH with or without captopril (Capt) treatment. Note that captopril treatment
lowered leptin levels within the carotid body in the IH (b) group. *, significantly different
from non-captopril IH treated animals. n=7.
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Effects of Captopril on OB-Rb and OB-R100 within Carotid Body: Captopril treatment
in either the normoxic controls (Fig. 5.5a) or the IH exposed (Fig. 5.5b) animals resulted
in a lower carotid body OB-Rb (Fig. 5.5a-b) protein levels (31% and 44%, respectively),
while the protein expression levels of OB-R100 (Fig. 5.5c-d) were increased to about
100% and 140% of the levels within the non-treated normoxic (Fig. 5.5c) and IH (Fig.
5.5d) animals, respectively. Additionally, when the effects of captopril in the normoxic
animals (Fig. 5.6a) were compared to those in of the IH animals (Fig. 5.6b), it was found
that captopril lowered in the IH animals the expression levels of the OB-Rb protein to
about 45% the normoxic controls (Fig. 5.6a). On the other hand, no differences were
found with the expression of the OB-R100 (Fig. 5.6b) between normoxic- and IH-captopril
treated animals.
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Figure 5.5. Western blots showing changes in OB-Rb (a-b) and OB-R100 (c-d) protein
within the carotid body following IH and captopril treatment. Note that captopril
treatment lowered Ob-Rb protein levels within the carotid body in both normoxic (Norm)
(a) and the IH (b) group. On the other hand, the protein levels of OB-R100 were increased
in both the normoxic (c) and the IH (d) groups. *, significantly different from noncaptopril treated animals within each group. n=7.
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Figure 5.6. Western blots showing changes in OB-Rb (a) and OB-R100 (b) protein within
the carotid body following captopril treatment in both the normoxic and IH groups. Note
that the protein level of Ob-Rb was significantly (*) lower in the IH animals compared to
the normoxic animals (a) treated with captopril. n=7.
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Effects of Captopril on STAT3, pSTAT3, SOCS3 and pERK 1/2 in the Carotid Body:
Figures 5.7-5.11 summarize the effects of captopril treatment on carotid body protein
expression of STAT3 (Figs. 5.7a-b and 5.8a), pSTAT3 (Figs. 5.7-c-d and 5.8b), SOCS3
(Fig. 5.9a-c), and pERK 1/2 (Figs. 5.10 and 5.11a-c) in normoxic and IH exposed
animals. Captopril treatment in normoxic animals resulted in decreased STAT3 protein
expression (Fig. 5.7a; to about 47% of non-treated group), whereas no differences were
found between IH-exposed animals (Fig. 5.7b) or between normoxic and IH animals
treated with captopril (Fig. 5.8a).

Captopril treatment in normoxic and IH exposed animals also resulted in
decreased pSTAT3 (52% and 49% of non-captopril treated animals, respectively) (Fig.
5.7c-d). Furthermore, pSTAT3 protein levels in the IH-captopril treated animals were
decreased to about 58% of normoxic-captopril treated animals (Fig. 5.8b).

Captopril treatment in normoxic and IH exposed animals also resulted in
increased SOCS3 protein expression within the carotid body. In normoxic animals,
captopril increased the expression of SOCS3 protein by almost 1036% (Fig. 5.9a), while
in the IH exposed animals captopril increased the expression of SOCS3 protein by about
2490% (Fig. 5.9b). However, the protein expression level of SOCS3 in the IH captopril
treated animals was reduced to about 70% of that found within the normoxic captopril
treated animals (Fig. 5.9c).

ERK1/2 and pERK 1/2 protein levels were decreased (to about 48% and 42% of
non-captopril treated animals, respectively) following captopril treatment (Fig 10a and c).
On the other hand, neither ERK 1/2 or pERK 1/2 protein levels in the IH captopril treated
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animals were different from those in the non-captopril treated IH exposed group (Fig.
5.10b and d) or from the normoxic captopril treated groups (Fig. 5.11).
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Figure 5.7. Western blots showing changes in STAT3 (a-b) and pSTAT3 (c-d) protein
within the carotid body following IH and captopril treatment. Note that captopril
treatment significantly (*) lowered STAT3 protein levels within the carotid body only in
normoxic (Norm) group (a). However, pSTAT3 levels were significantly (*) lower in
both the normoxic (c) and the IH (d) groups after captopril treatment. n=7.
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Figure 5.8. Western blots showing changes in STAT3 (a) and pSTAT3 (b) protein within
the carotid body following captopril treatment in both the normoxic and IH groups. Note
that the protein level of pSTAT3 was significantly (*) lower in the IH animals compared
to the normoxic animals (b) treated with captopril. n=7.
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Figure 5.9. Western blots showing changes in SOCS3 protein expression within the
carotid body following IH and captopril treatment. Note that captopril treatment
significantly (*) elevated SOCS3 protein levels within the carotid body in the normoxic
(Norm) (a) and IH group (b). However, SOCS3 levels were significantly (*) lower in the
IH captopril treated group compared to the normoxia captopril treated group (c). n=7.
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Figure 5.10. Western blots showing changes in ERK 1/2 (a-b) and pERK 1/2 (c-d)
protein within the carotid body following IH and captopril treatment. Note that captopril
treatment significantly (*) lowered ERK 1/2 and PERK 1/2 protein levels within the
carotid body only in normoxic (Norm) group (a and c). n=7.
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Figure 5.11. Western blots showing changes in ERK 1/2 (a) and pERK 1/2 (b) protein
within the carotid body following captopril treatment in both the normoxic and IH
groups. Note that the protein levels were not altered in either group treated with captopril.
n=7.
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5.4 Discussion
These data provide the first direct evidence that ANG II is important in the
regulation of leptin not only within the carotid body, but also within the circulation, and
that ANG II contributes to changes in downstream leptin signaling within the carotid
body during IH. These conclusions are based on the findings that within the carotid body,
cells that expressed leptin or the OB-Rb also expressed the AT1R and AT2R.
Additionally, inhibition of ANG II by blocking ACE decreased leptin not only within the
carotid body, but also the plasma levels of leptin during IH. Furthermore, the decrease in
available leptin to the carotid body was accompanied by a decrease in the OB-Rb in
captopril treated animals, which suggests a dampening of the entire leptin signaling
system within the carotid body. This suggestion is consistent with the observation that
captopril treatment resulted in a decrease in the activation of STAT3 into pSTAT3,
supporting the notion of a reduction in OB-Rb signaling. Finally, contrary to the decrease
in OB-Rb protein expression levels following captopril treatment, OB-R100 protein levels
in the carotid body were increased suggesting an either an increase in transport of leptin
out of cells or an increase in leptin degradation within the cells. Taken together, these
data can be interpreted to suggest that ANG II effects on carotid body chemosensitivity
may be mediated in part through the carotid body leptin system, and that ANG II
signaling is critical for the maintenance of circulating levels of leptin in normoxia and
during IH. This suggestion is consistent with the finding that AT1R blockade produces
decreased BMI and food intake, but has no effect in obese Zucker rats with a genetic
mutation in the leptin receptor (Muller-Fielitz et al., 2011). In addition, it has been shown
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that the brain RAS facilitates renal and brown adipose tissue sympathetic nerve responses
to leptin (Hilzendeger et al., 2012).
The finding of a decrease in circulating leptin following ANG II inhibition is
consistent with earlier data suggesting that ANG II signaling stimulates not only leptin
production, but also leptin secretion (Cassis et al., 2004; Premaratna et al., 2012).
Considering that the main production/secretion site of leptin into the plasma is adipose
tissue (Lonnquist et al., 1996; Caro et al., 1996), this study provides further evidence
suggesting that the leptin system may be in part under the control of ANG II. This latter
suggestion is consistent with the observation in a mouse model deficient in the AT1Ra
isoform, in which plasma leptin concentrations were found to be reduced when compared
to wild-type (Kaneko et al., 2011).
Carotid body leptin levels were also found to be decreased in animals treated with
captopril during both normoxia and IH conditions. This finding is similar to that observed
within adipocytes taken from rats treated with captopril, in which both circulating leptin
and leptin release was decreased (Cassis et al., 2004). Additionally, incubation of
adipocytes with ANG II resulted in an up-regulation of leptin mRNA, as well as leptin
secretion (Cassis et al., 2004) while in ventricular myocytes, ANG II promotes de novo
synthesis and secretion of leptin (Rajapurohitam et al., 2006). Furthermore, blocking OBR’s in these cardiomyocytes prevented the hypertrophic effects ANG II normally has on
these cells suggesting that leptin may mediate effects normally attributed to direct ANG
II action (Rajapurohitam et al., 2012). Finally, in human vascular smooth muscle cells, it
has been previously found that increased ANG II results in increased leptin protein and
mRNA expression (Shyu et al., 2012). Thus, it is not unreasonable to suggest that leptin
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may be involved in mediating some of the changes in carotid body chemosensitivity
normally attributed to ANG II (Gomez-nino et al., 1990; Eyzaguirre and Zapata, 1968;
Bock, 1980). Interestingly, the increased leptin protein and mRNA expression observed
in human vascular smooth muscle cells as a result of the elevated ANG II has been
attributed to increases in reactive oxygen species (Shyu et al., 2012). The IH induced
changes in the carotid body chemosensitivity have been suggested to be related to an
enhanced reactive oxygen species production (Pawar et al. 2009; Iturriaga et al., 2009). In
addition, the IH effects associated with increases in superoxide have been shown to be
blocked by losartan, a specific AT1R blocker (Marcus et al., 2010). Therefore, taken
together, these data suggest a possible mechanism by which ANG II signaling may
modulate ROS activity and subsequently leptin activity within the carotid body.
Captopril treatment in both normoxia and after IH reduced protein levels of OBRb compared to their respective controls. This finding suggests that ANG II plays an
important role in the regulation of Ob-Rb although, due to the low levels of available
leptin both locally and from the circulation following captopril treatment, ligand-induced
endocytosis seems unlikely (Bennett et al., 1998; Uotani et al., 1999). The short-form
leptin receptor displayed increased protein expression in the carotid bodies following
captopril-treated animals in both the normoxic and IH conditions. Generally, OB-Ra is
believed to be involved in leptin transport, specifically across the blood-brain barrier
(Banks et al., 1996; Golden et al., 1997; Bjorbaek et al., 1998). One potential explanation
may be that the reduced leptin availability stimulates OB-Ra protein expression to aid in
leptin secretion from glomus cells. Additionally, the OB-Ra has been suggested to
function in the degradation process of leptin (Iida et al., 1996; Merabet et al., 1997;
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Sharma et al., 1997) and may provide one mechanism through which the decreases seen
in carotid bodies occurs. However, the functional significance of ANG II effects on ObRa is unknown.
The decreased protein expression of leptin and OB-Rb in the carotid bodies after
captopril treatment is consistent with the decreases in activation of STAT3. In normoxic
and IH conditions, captopril treatment reduced pSTAT3 levels, a downstream signaler
involved in OB-Rb activation (Elmquist et al., 1997; Fruhbeck, 2006; Wang et al., 1998;
Huo et al., 2006, 2007). The down regulation of both the ligand and the receptor would
be expected to result in a decrease in activation of the signaling pathway (Elmquist et al.,
1997; Fruhbeck, 2006; Wang et al., 1998; Huo et al., 2006, 2007). One other potential
explanation for the decrease in pSTAT3 levels found in captopril treated animals is the
decrease in ANG II levels as ANG II signaling, through AT1R, can activate the
JAK/STAT pathway resulting in phosphorylation of STAT3 (Ji et al., 2012; Omura et al.,
2001). However, it has also been shown that leptin injections resulted in up-regulation of
pSTAT3 protein expression (Messenger et al., 2012), and thus this decrease after ANG II
inhibition most likely occurs at least in part through decreased leptin signaling.
Consistent with the decrease in pSTAT3 is the concomitant rise in SOCS3 levels.
SOCS3 acts as a negative feedback loop on JAK/STAT signaling (Bjorbaek et al., 2000;
Fruhbeck et al., 2006). The decrease in pSTAT3 accompanied by the SOCS3 rise would
be expected in the IH condition, which has previously been shown to stimulate the
JAK/STAT pathway (Messenger et al., 2012; Messenger & Ciriello, 2012). In some cell
types, ANG II has been known to stimulate the JAK/STAT pathway which results in
increased SOCS3 expression (Calegari et al., 2003; Ji et al., 2012; Omura et al., 2001).
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However, as to the reason why such a profound increase was found in both the normoxic
and IH condition is unknown.
In addition to the JAK/STAT pathway, OB-Rb signaling can also activate the
MAPK cascade (Bjorbaek et al., 1997; Banks et al., 2000) and thus activation of ERK1/2
is an indicator of pathway activation. In normoxic animals, captopril treatment resulted in
a decrease in pERK1/2 protein levels, however no changes were observed in the IH
animals. This finding suggests during IH, other mechanisms in addition to leptin
(Bjorbaek et al., 1997; Banks et al., 2000) or ANG II (Li et al., 1998; Nakai et al., 2012)
may activate ERK1/2.
In summary, this study has demonstrated that the RAS modulates the leptin
system not only in the circulation, but also within chemosensitive carotid body. Inhibition
of ANG II by ACE results in a dampening effect on circulating leptin levels as well as
local carotid body leptin protein levels. There is also a decrease in the OB-Rb and
downstream indicators of OB-Rb activation. Angiotensin signaling through the AT1R is
thought to be critical for chemosensitivity by the carotid bodies (Marcus et al., 2010), and
given its co-localization with OB-Rb and leptin within the glomus cells suggests that
AT1R has a stimulatory effect on the carotid body leptin system and ANG II
chemosensitive role may be mediated in part through leptin signaling.
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Chapter 6

6

Conclusions
6.1 Conclusions Chapter 2


Carotid bodies, afferents in carotid sinus nerve and petrosal/nodose ganglia
express long form of leptin receptor (Ob-Rb).



Intermittent hypoxia (IH) in conscious animal elicits an increase in plasma levels
of leptin.



IH induces pSTAT3 and fos/Fra-1 proteins expression in carotid body cells of
these animals.



IH induces immediately early gene fos/Fra-1 expression in petrosal and nodose
ganglion cells.



Systemic injections of leptin in anesthetized animals induces pSTAT3 and
fos/Fra-1 protein expression in carotid body cells, and fos/fra-1 in petrosal/nodose
ganglia cells.



These data suggest that leptin released during IH may modulate the activity of
peripheral chemoreceptor reflex.

6.2


Conclusions Chapter 3

Carotid bodies express leptin, and the long form (Ob-Rb) and short form (ObR100) leptin receptors.



Intermittent hypoxia (IH) in conscious animal elicits an increase in plasma levels
of leptin.
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IH induces leptin, Fra-1, Ob-R100, pSTAT3, ERK 1/2 and SOCS3 protein
expression in carotid body glomus cells, while down-regulating Ob-Rb.



Intravenous injections of leptin induce leptin and Fra-1 expression in carotid body
cells.



Data suggest that leptin released during IH may modulate the activity of carotid
body glomus cells and the carotid chemoreceptor reflex.

6.3


Conclusions Chapter 4

Carotid bodies express leptin, and the long form (OB-Rb) and short form (ObR100) leptin receptors.



Conscious animals were exposed to short term (7 days) and long term (95 days)
chronic intermittent hypoxia (CIH).



CIH induced changes in leptin, OB-Rb, pSTAT3, SOCS3 and pERK 1/2 protein
expression in carotid body glomus cells.



Data suggest that leptin, through its receptor and downstream signaling proteins,
may contribute to alterations in carotid chemoreceptor sensitivity.

6.4


Conclusions Chapter 5

Carotid bodies express the angiotensin type-1 receptor (AT1R) which is coexpressed in cells expressing leptin and the long-form leptin receptor (OB-Rb).
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Angiotensin converting enzyme (ACE) inhibition decreases circulating and
carotid body leptin protein expression in normal animals and in IH-exposed
animals.



ACE inhibition affects downstream signaling proteins of OB-Rb signaling.



Data suggest angiotensin signaling modulates carotid body leptin signaling
activity.

6.5 Overall Conclusion
Taken together, the data presented describe an active leptin-signaling system within
the carotid body which may play an important role in modulating the carotid
chemoreceptor reflex and describe a potential angiotensin-related mechanism by which
these changes come about. The data provide evidence for conditions during IH where
both circulating and local, carotid body-produced leptin are increased and may influence
the activity of type-I glomus cells of the carotid body. Additionally, the leptin produced
by type-I cells may act both pre- and post-synaptically to signal in an autocrine/paracrine
fashion in the carotid body or signal within the CNS to exert an action on the carotid
chemoreceptor reflex.
Exposure to IH for differing amounts of time has varying effects on downstream
indicators of leptin signaling within the carotid body which may be due to activation of
homeostatic mechanisms that change circulating factors, such as catecholamines,
angiotensin II and leptin itself. Additionally, the sympathetic efferent innervation of the
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carotid body may play a role in the leptin system as it is well known to affect leptin
production and secretion in tissue such as adipocytes and may be of interest in future
studies.
The finding of an active leptin system within the carotid body has major implications
in conditions of increased circulating leptin including OSA and obesity. The findings
provide a pathway by which SNA and thus arterial pressure may be elevated in these
cases, specifically during daytime normoxia in OSA patients. Further studies are required
to disover the exact role of leptin within the carotid chemoreceptor reflex, specifically
whether it alters glomus cell activity only, altering sensitivity of the cells or inducing
transmitter release, or whether it can act directly on PG nerve terminals and directly
signal the reflex.
Future studies should involve the use of OB-Rb-deficient animals, leptin deficient
animals and administration of a leptin antagonist to confirm that the activation of
downstream OB-Rb signalers are indeed due to leptin signaling and not from other
potential mechanisms, such as angiotensin signaling. Electrophysiological (patch clamp)
studies using type-I cells in culture would be critical in determining the effect of leptin on
both the function of type-I cells as well as on petrosal ganglion neurons or carotid sinus
nerve afferents. Furthermore, Ca2+ imaging of glomus cells may provide evidence of
leptin’s cellular action on chemoreceptor cell sensitivity to PO2. Coupled with the Ca2+
imaging, the media in which these cells are cultured should also be investigated to
determine which, if any, peptides are secreted as a result of leptin application, including
leptin itself. Additionally, ANG II application to these carotid body cells in culture may
help support the idea of ANG II modulates the leptin system.
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Many of the studies presented in this manuscript would benefit from qPCR
techniques. One criticism of the results, specifically leptin levels in the carotid body, is
the fact it is not directly known how the changes come about. The increases or decreases
in leptin levels may come about by changes in production, secretion or degradation and
mRNA levels may give a better indication of which mechanism is occurring.
Finally, using an in vivo approach, physiological measurements including blood
pressure, sympathetic and phrenic nerve activity would be critical in elucidating the
function of leptin in the carotid body to chemoreception. Particularly useful would be
analyzing physiological measurements of chemosensitivty using the OB-Rb-deficient
Zucker rat or a leptin-deficient animal model.
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